1

CURRICULUM VITAE

Wang, Ena

Research Chief, Division of Translational Medicine

Sidra Medical and Research Center

Doha, Qatar

ewang@sidra.org

EDUCATION:

1986-1989

Master of Medicine, Shanghai Medical University (Fudan University), Shanghai, P.R. China.

1978-1983

M.D. Hebei Medical University, Shijiazhuang, Hebei Province, P.R.China.

PROFESSIONAL EXPERIENCE:

2014 Feb-Present

Research Chief of Translational Medicine Division (DTM) at Sidra Medical and Research Center,

Doha, Qatar. Chair of Research and Management Committee. Member of Sidra IRB board.

Responsible for the Translational research infrastructure building and research program development.

Lead a team of 19 outstanding principle investigators and 47 research scientists currently aiming future

fully staff of 180 FTE. Key player in National Qatar Genome Project.

The DTM institutes the following key programs:

1. The largest Clinical Genomic Lab (CGL) in Middle East responsible for all NGS based

research and clinical diagnosis. It is the only entity leading the Qatar Genome Project for high quality data

generation and have completed the pilot 3000 whole genome sequence within 1 year from instrument set

up, testing, SOP, QC metrics implementation.

2. Omics Core facility serves centralized biorepository, automated sample process and QC, SNP

genotyping, gene expression, biomarker validation and PacBio based sequencing for structure variants,

splicing variants and microbiome full length analysis.

3. Deep Phenotyping Core (DPC) responsible for the state of art FACS analysis and cell sorting,

Somomer protein profiling, confocal-two photon life image and 3D image analysis, protein MS,

metabolic MS and biochemical analysis.

4. Clinical Research Center (CRC) responsible for clinical gene cell therapy and bone marrow

transplant product development and production under GMP; clinical trial monitor, management,

regulatory comply and QA.

5. Research programs:

a. Cancer biology and Immunotherapy;

b. System biology for disease dissection;

c. Center for inflammation research program (infection, microbiome, nutrigenomics,

imaging biology);

d. Human genetic disorders focusing on Mendelian disorders, constitutional disease,

genodermatosis, primary immune deficiency and causal variants functional validation for

new therapy discovery.

2

2013-2014

Acting Section Head of Infectious Disease and Immunogenetic Section, in Department of

Transfusion Medicine (DTM), Clinical Center, NIH

2009-2014

Associated Director of Trans NIH Center for Human Immunology. Omics Facility Head, National

Institutes of Health (NIH)

Responsible and participate multiple clinic study design; Development of standard operation procedures

(SOP) for clinic sample collection, processing, bio repository tracking; Direct Omics facility for

technology development, validation, instrumentation selection, platform validation; Management lab

operation, data generation, data analysis, data coordination with clinician, bioinformatician and team of

deep phenotyping, Responsible research budget plan, personnel management and evaluation.

2007-2014

Director of Molecular Science in Department of Transfusion Medicine (DTM), Clinical Center, NIH Supervisor of: 1) Immunogenetics laboratory; 2) Molecular Diagnostics Laboratory; 3) Transfusion

Transmitted Virus (TTV) diagnostic laboratory. The position includes the supervision of 24 scientists and

technicians involved in several aspect of service and research provided by DTM as part of the NIH

Clinical Center mission.

2001-2014

Staff Scientist – Infectious Disease and Immunogenetic Section (Director Dr. Francesco Marincola),

Department of transfusion medicine (DTM), NIH Clinical Center. Responsible for the development of functional genomic, molecular genetics and molecular biology

technology - Supervisory post-doctoral fellows and graduate/under graduate students - Consultant to other

DTM, Clinical Center (CC) and NIH staff - Evaluation and development of assay technologies to

enhance, supplement, and provide expedites to multiple ongoing clinical studies.

1998-2001

Cancer Research fellow - Surgery Branch, National Cancer Institute, National Institute of Health (Dr.

Francesco Marincola's Lab)

Responsible for development of novel techniques such as RNA amplification, gene profiling arrays,

monitoring of gene expression patterns using high-throughput cDNA arrays by amplification of fine

needle aspiration (FNA) samples obtained from tissues undergoing therapy and/or micro-dissected

specimens - Developed tetrameric epitope/HLA (t-HLA) complexes for epitope-specific T cell

monitoring - Responsible for lab management, student training, scientific trouble shooting and

collaborations

1995-1997

Assistant Research Scientist. Arizona Cancer Center, University of Arizona, Tucson, AZ (Dr. Douglas

F. Lake's Laboratory).

The main project included isolation T- and B-lymphocytes from tumor tissue and peripheral blood -

Identification, cloning and sequencing of tumor specific T-cell receptor genes. Preparation of single-chain

T cell receptors and protein expression using pET21d system - Use of PCR to introduce point mutations

on the p53 gene for transfection of mouse cell lines with the mutant - Detection of mutant p53 protein by

ELISA (antigen capture), immunohistochemistry staining - Western blot or RIPA (radio-immune

precipitation assay) and mutant p53 gene on transgenic cell line by PCR and RT-PCR

1994-1995

Assistant Research Scientist, Department of Microbiology and Immunology, AHSC, University of

Arizona (Dr. Emmanuel Akporiaye's Laboratory)

3

Carried out HLA-B7 human cancer gene therapy project including the transfection of cytokine genes into

human tumor cells - Cloning and sequencing of the murine CIITA gene - Development of murine TGF-

anti-sense transfection model - Cloning of human anti-sense TGF- sequence

1991-1994

Visiting Research scientist. Department of Microbiology and Immunology, AHSC, University of

Arizona (Dr. John J. Marchalonis Laboratory)

Project: Evolution of the immune system: Purification and characterization of lectin from lamprey eggs

and molecular cloning of the lectin gene. Project 2: Mechanism of Autoimmune diseases: The studies of

auto-antibody against T-cell receptor in the rheumatoid arthritis, SLE patients and normal subjects.

1989-1991

Research Scientist. Doctor in Chief, Shanghai Dermatology Institute - Shanghai, R.C. China Research project: Identification of allergen specific in vivo and in vitro reactions and immunotherapy of

atopic dermatitis.

1986-1989

Graduate Research Assistant - Division of Allergy and Allergen Studies, Department of Parasitology -

Shanghai Medical University (Fudan University), Shanghai China Carried out characterization and standardization of allergens from house dust mite extracts while

becoming skilled in protein purification and immunochemical analysis including ELISA, SDS-PAGE,

Western blotting, IEF, 2-D electrophoresis, chromatography (affinity, gel filtration, ion exchange), radio-

immune precipitation analysis and RAST.

1983-1986

Teaching Associate - Department of Parasitology, Chengde Medical College - Hebei Province, P.R.

China Teaching medical parasitology to medical students. Ecological studies on mosquitoes in the Chengde

area, Hebei Province, P.R. China.

Society Memberships:

American Society for Cell Biology (1999-present)

American Society of Histocompatibility and Immunogenetics (2001-present)

International Society for Biological Therapy of Cancer (2003-present)

Honors:

Adjunct Professor Peking Union Medical College, Beijing, China (2004 – present)

Adjunct Professor Shanghai Medical College, Fudan University, Shanghai China (2009-present)

Adjunct Professor Southern Medical University, Guangzhou, China (2010-present)

Awards:

1. Investigator Travel Fellowships Award from 53rd Annual Symposium on Fundamental Cancer Research

November 2000.

2. Investigator Travel Fellowship Award. FOCIS meeting, Boston, May 2001.

3. Recipient NIH 2002-2003 Bench to Bedside Award ($ 200,000). 2002.

4. Recipient of minority award - Minority Trainee Research Forum - San Diego, California, March 16-18,

2002. (As principal investigator).

5. Recipient of NCI Director’s 2006 Intramural Innovation Award, 2006 ($50,000). (As co-investigator).

4

6. Recipient of Clinic Center Director’s Award for supervising molecular activities and advising the

Department of Transfusion Medicine on development of advanced molecular technology. 2007

7. Recipient of Clinic Center Director’s Award in the category of Science, bestowed in recognition of

outstanding leadership in translating emerging molecular genetics concepts into useful tools for the

support of Trans-NIH initiatives. 2010

8. Special Act on Service Award: accomplishment in building a state of the art Genomics facility at CHI.

2012, NIH Clinical Center.

Editor for journals:

Deputy Editor Journal of Translational Medicine (a BioMed Central Journal)

Editorial Board Member Current Immunology Reviews

Editorial Board Member Genetic Medicine

Associated Editor Immunotherapy

Associated Editor BMC Immunology

Associate editor Clinical and Translational Medicine

Editorial Board Member Journal for immunotherapy of cancer (JITC)

Reviewing Editor:

Nucleic Acid Research, Genome, Genomics, Biotechniques, Nature Biotechnology, Biomolecular

engineering, Physiological Genomics, J of biotechnology. Review Editorial Board of Frontiers in Tumor

Immunity

Chairman organizing committee:

Organizer of Cancer Biometrics Workshop: Identifying Biomarkers and Surrogates of Tumor in Patients.

The 18th Annual Meeting of the international Society of Biological Therapy for cancer. 2003. USA

Orgnizer SITC Workshop on Personalized Cancer Immunotherapy, November 7, 2013, Bethesda, MD

USA.

Organizer of Melanoma bridge annual meeting. Naples, Italy, December, 2009-2014.

Chair of Advances of proteomics in personalized medicine symposium. Nov 15-16th. 2014, Doha, Qatar.

Organizer of Opportunities and challenges in Stem cell research and therapy developments. 24th – 25th of

March 2015 in Doha, Qatar.

Chair of Functional Genomics Annual Symposium Dec 11-12th, 2015, Doha, Qatar.

Scientific advisory board member:

Melanoma Molecular Map Project at http://www.mmmp.org/MMMP/welcome.mmmp

Advisory Board for The 3rd Oncology Biomarkers Conference held in January 27-28, 2011 in San Diego,

CA.

Scientific Advisory Board member of Center of Excellence of mass spectrometry, Lund University,

Sweden. 2013-present

Faculty 2010-2013 Cancer Education Consortium, 80 W. Madison Avenue, Dumont, New Jersey 07628

♦ (201)338-2537A not-for-profit 501 (c) (3) educational foundation #04-3598412

2011-present Member of Cancer Immunotherapy trial network

2009-Present Scientific Board of Melanoma Bridge, Naples, Italy

Member of Qatar Genome Committee (QGP) since 2014 and QGP publication committee since

2016.

Publications-Peer-Reviewed Articles:

5

1) Wen, T., Wang, E., Shen, S., Jiang, C., Tian, R., Kang, K. and Zhu, J. Allergenic potency of SMU-Df

extract in comparison with VUS- Df extract; and diagnosis and immunotherapy for atopic dermatitis and

rhinitis with SMU-Df extract in China. Arbeiten aus dem Paul EhrlichInstitut Bundesamt fur Sera und

Impfstoffe Zu Frankfurt Am, 1992. 85: 217-27.

2) Schluter, S.F., Schroeder, J., Wang, E. and Marchalonis, J.J. Recognition molecules and immunoglobulin

domains in invertebrates. Ann New York Acad Sciences, 1994. 712: 74- 81.

3) Marchalonis, J.J., Schluter, S.F., Wang, E., Dehghanpisheh, K., Lake, D., Yocum, D.E., Edmundson, A.B.

and Winfield, J.B. Synthetic autoantigens of immunoglobulins and T- cell receptors: their recognition in

aging, infection, and autoimmunity. Proc Soc Exp Biol & Med 1994. 207: 129- 47.

4) Lake, D.F., Schluter, S.F., Wang, E., Bernstein, R.M., Edmundson, A.B. and Marchalonis, J.J.

Autoantibodies to the alpha/beta T-cell receptors in human immunodeficiency virus infection: dysregulation

and mimicry. Proc Nat Acad Sci, USA, 1994. 91:10849-53.

5) Park, J.A., Wang, E. Kurt, R.A., Schluter, S.F., Hersh, E.M. and Akporiaye, E.T. Expression of an antisense

transforming growth factor-§1 transgene reduces tumorigenicity of EMT6 mammary tumor cells. Cancer

Gene Therapy, 1997.4 : 42-50.

6) Panelli, M.C., Wang, E., Shen, S., Schluter, S.F., Bernstein, R.M., Hersh, E.M., Stopeck, A., Gangavalli, R.,

Barber, J., Jolly, D., and Akporiaye, E.T. Interferon-g gene transfer of an EMT6 tumor that is poorly

responsive to IFN-g stimulation: increase of tumor immunogenicity is accompanied by induction of a mouse

class II transactivator and class II MHC. Cancer Immunol Immunother, 1996. 42: 99-107.

7) Riker AI, Kammula US, Panelli MC, Wang E, Ohnmacht G, Steinberg SM, Rosenberg SA and Marincola FM.

Threshold levels of gene expression for the melanoma antigen gp100 determine tumor cell recognition by

cytotoxic T lymphocytes. Int J cancer 86 (6): 818-826, 2000.

8) Riker A, Cormier J, Panelli M, Kammula U, Wang E, Abati A, Fetsch P, Lee KH, Steinberg S, Rosenberg S,

Marincola F. Immune selection after antigen-specific immunotherapy of melanoma. Surgery. 1999

Aug;126(2):112-20.

9) Riker AI, Panelli MC, Kammula US, Wang E, Wunderlich J, Abati A, Fetsch P, Rosenberg SA and Marincola

FM. Development and Characterization of Melanoma Cell Lines Established by Fine Needle Aspiration

Biopsy: Advances in Monitoring Patients with Metastatic Melanoma. Cancer Det Prev. 23 (5): 387-396, 1999.

10) Lee K-H, Wang E, Nielsen M-B, Wunderlich J., Migueles S, Connors M., Steinberg S., Rosenberg SA and

Marincola FM. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with

increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol. 163: 6292-

6300, 1999.

11) Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA and Marincola FM. Phase I study in

patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the

melanoma associated antigens MART-1 and gp100. J Immunother 23 (4): 487-498, 2000.

12) Kammula US, Lee K-H, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA and Marincola FM. Functional

analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood

mononuclear cells and tumor specimens. J Immunol. 163: 6867-6875, 1999.

6

13) Panelli MC, Riker A, Kammula U, Wang E, Lee K-H, Rosenberg SA and Marincola FM: Expansion of

tumor-T call pairs form fine needle aspirates of melanoma metastases. J Immunol 2000, 164 (1): 495-504,

2000.

14) Wang E, Miller L, Ohnmacht GA, Liu E and Marincola FM. High fidelity mRNA amplification for gene

profiling. Nature Biotech. 18 (4): 457-459, 2000.

15) Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A,

Dougherty E, Wang E, Marincola FM, Gooden C, Lueders J, Glatdelter A, Pollock P, Gillanders E, Dietrich K,

Alberts D, Sondak V, Hayward N and Trent J. Molecular classification of cutaneous malignant melanoma by

gene expression: shifting from a continuous spectrum to distinct biologic entities. Nature. 406: 536-540, 2000.

16) Nielsen M-B, Monsurro’ V, Migueles S, Wang E, Ainhoa Perez-Diez, Lee K-H, Kammula U, Rosenberg SA

and Marincola FM. Status of activation of circulating vaccine-elicited CD8+ T cells. J Immunol. 165 (4): 2287-

2296, 2000.

17) Monsurro’ V, Nielsen M-B, Perez-Diez A, Dudley M, Wang E, Rosenberg SA and Marincola FM. Kinetics of

T cell receptor utilization in response to repeated epitope-specific immunization. J Immunol. 166: 5817-5825,

2001.

18) Mocellin S, MD, Ohnmacht GA, MD, Wang E, MD and Marincola FM, MD. Kinetics of cytokine expression

in melanoma metastases classifies immune responsiveness. Int J Cancer 93,236-242, 2001.

19) Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch PA, Rosenberg SA and Marincola FM. Short-

term kinetics of tumor antigen expression in vivo. J Immunol. 167(3): 1809-1820, 2001.

20) Mocellin S, Wang E, and Marincola FM. Cytokines and immune response in the tumor microenvironment. J

Immunother. 24 (5): 392-407, 2001.

21) Mocellin S, Fetsch P, Abati A, Phan G, Wang E, Provenzano M, Stroncek D, Rosenberg SA, Marincola FM.

Laser scanning cytometer evaluation of MART-1, gp100 and HLA-A2 expression in melanoma metastases. J

Immunother. 24 (6): 447-458, 2001.

22) LePoole IC, Riker AI, Quevedo ME, Stennett LS, Wang E, Marincola FM, Kast WM, Robinson JK and

NIckoloff BJ. Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells

by cytotoxic T cells. Am J Pathol. 160 (2): 521-528, 2002

23) Monsurro’ V, Nargorsen D, Wang E, Provenzano M, Dudley ME, Rosenberg SA and Marincola FM.

Functional heterogeneity of vaccine-induced CD8+ T cells. . J Immunol 168: 5933-5942, 2002.

24) Seiter S, Monsurro’ V, Nielsen M-B, Wang E, Provenzano M., Wunderlich JR, Rosenberg SA and Marincola

FM. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured

tumor infiltrating lymphocytes. J Immunother, 25 (3), 252-263, 2002.

25) Wang E, LD Miller, GA Ohnmacht, S Mocellin, A Perez-Diez, DP, Y Zhao, R Simon, JI Powell, E Asaki,

HR Alexander, PH Duray, M Herlyn, NP Restifo, ET Liu, SA Rosenberg, FM Marincola. Evolving

molecular portraits of metastatic melanoma. Cancer Res 62 (13): 3581-3586, 2002.

26) Feldman AL, Costouros NG, Wang E, Qian M, Marincola FM, Alexander RH, and Libutti SK. Advantages

of mRNA amplification for microarray analysis. BioTechniques. 33(4):906-914, Oct. 2002.

7

27) Nagorsen D., Monsurro’ V, Wang E and Marincola FM. Characterization of CD8 negative, HLA class I /

epitope tetrameric complexes (tHLA) binding T cells. J Immunother. 25 (5): 379-384, 2002.

28) Nagorsen D, Monsurro V, Wang E, and Marincola FM. Characterization of CD9 negative, HLA class I epitope

tetrameric complexes binding T cells. J Immunother. 25 (6): S2, Dec 2002.

29) Panelli CM, Martin B, Nagorsen D, Wang E, Smith K, and Marincola FM. Genomic and proteomic

profiling of PBMC and tumor microenvironment following stimulation with high doses IL-2 .17th Annual

Meeting for the Society of Biological Therapy, San Diego, Nov7-10, 2002. . J Immunother. 25 (6) S3 ,Dec

2002.

30) Panelli MC, Martin B, Nagorsen D, Wang E, Smith K and Marincola FM. A genomic and proteomic-based

hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific

immunization. Cells Tissues Organs 177: 124-131, 2004.

31) Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, Wang E, Young HA,

Murphy PM, Hwu P. Redirecting migration of T cells to chemokine secreted from tumors by genetic

modification with CXCR2. Hum Gene Ther 13(16):1971-80, Nov 2002.

32) Wang E, Adams S, Zhao Y, Panelli MC, Klein H and Marincola FM. A strategy for detection of known and

unknown SNP using a minimum number of oligonucleotides. J Transl Med 1:4, 2003.

33) Jin P, Zhao Y, Ngalame Y, Panelli MC, Nagorsen D, Monsurró V, Smith K, Hu N, Su H, Taylor PR,

Marincola FM and Wang E. Selection and validation of endogenous reference genes using a high throughput

approach. BMC Genomics, 5 (1): 55, 2004.

34) Wang E, Lichtenfels R, Bükur J, Ngalame Y, Panelli M, Seliger B and Marincola FM. Ontogeny and

Oncogenesis Balance the Transcriptional Profile of Renal Cell Cancer. Cancer Res 2004, 64:7279–7287.

35) Wang E, Nglame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary C, Freedman

RS and Marincola FM. Peritoneal and Sub-Peritoneal Stroma May Facilitate Regional Spread of Ovarian

Cancer. Clin Cancer Res 2005, 11:113-122.

36) Freedman RS, Deavers M, Lir J and Wang E. Peritoneal inflammation-A microenvironment for epithelial

ovarian cancer (EOC). J Transl Mede 2004, 2:23 (25 Jun 2004).

37) Panelli MC, Martin B, Nagorsen D, Wang E, Smith K and Marincola FM. A genomic and proteomic-based

hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific

immunization. Cells Tissues Organs 177: 124-131, 2004.

38) Mocellin S, Panelli MC, Wang E, Rossi CR, Pilati P, Nitti D, Lise M and Marincola FM. IL-10 stimulatory

effects on human NK cells explored by gene profile analysis. Genes and Immunity, 5: 621-630, 2004.

39) Wang E, Panelli MC, Zavaglia K, Mandruzzato S, Hu N, Taylor PR, Seliger B, Zanovello P, Freedman RS

and Marincola FM. Melanoma-restricted genes. J Transl Med 2004, 2:34.

8

40) Monsurró V, Wang E, Yamano Y, Migueles SA, Panelli MC, Smith K, Nagorsen D, Connors M, Jacobson S

and Marincola FM. Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood

2:2004 Oct 1, 104(7):1970-8 Epub 2004 June 08.

41) Panelli MC, Wang E and Marincola FM. The biology behind: the pathway to biomarker discovery: carbonic

anhydrase IX and the prediction of immune responsiveness. Clin Cancer Res - 11(10): 3601-3603, 2005.

42) Panelli MC, White R, Foster M, Martin B, Wang E, Smith K and Marincola FM. Forecasting the cytokine

storm following systemic interleukin-2 administration. J Transl Med 2: 17, 2004.

43) Aricó E, Wang E, Tornesello ML, Tagliamonte M, Lewis GK, Marincola FM, Buonaguro FM and Buonaguro

L. Immature monocyte derived dendritic cells gene expression profile in response to virus-like particles

stimulation. J Transl Med 3: 45, 2005.

44) Stroncek DF, Basil C, Nagorsen D, Deola S, Aricó E, Smith K, Wang E, Marincola FM and Panelli MC.

Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms.

Journal of Translational Medicine, 2005,3:24

45) Rossi L, Martin B, Hortin G, White R, Foster M, Wang E, Stroncek D, Marincola FM and Panelli CM. High

dose IL-2 inflammatory profile. Proteomics. 2006 Jan;6(2):709-20.

46) Mandruzzato S, Callegaro A, Turcatel G, Francescato S, Montesco C, Chiarion-Sileni V, Rossi CR, Bicciato

S, Wang E, Marincola FM and Zanovello P. A gene expression signature associated with survival in

metastatic melanoma. J Transl Med 4: 50, 2006.

47) Kaufman HL, DeRaffele G, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS, Cheung K, Lee DS,

Divito J, Voulo M, Donovan J, Dolan K, Manson K, Panicali D, Wang E, Horig H and Marincola FM.

Targeting the local tumor microenvironment with vaccinia virus expressing B7.21 for the treatment of

melanoma. J Clin Invest 2005, doi:10.1172/JC124624.

48) Panelli MC, Wang E and Marincola FM. The biology behind - The pathway to biomarker discovery:

carbonic anhydrase IX and the prediction of immune responsiveness. Clin Cancer Res. 2005 May

15;11(10):3601-3.

49) Conejero-Goldberg C, Wang E, Yi C, Goldberg TE, Jones-Brando L, Marincola FM, Webste MJ,and Torrey

EF. Infectious Pathogen Detection Arrays: Viral Detection in Cell Lines and Postmortem Brain Tissue.

Biotechniques, 39:741-751, 2005.

50) Nagorsen D, Deola S, Smith K, Wang E, Monsurro V, Zanovello P, Marincola FM and Panelli MC. Polarized

monocyte response to cytokine stimulation. Genome Biol, 2005, 6:R15.

51) Wang E, Voiculescu S, Le Poole IC, El-Gamil M, Li X, Sabatino M, Robbins PF, Nickoloff BJ, Marincola

FM. Clonal persistence and evolution during a decade of recurrent melanoma. J Invest Dermatol. 2006

Jun;126(6):1372-7.

52) Basil CF, Zhao Y, Zavaglia K, Jin P, Panelli MC, Voiculescu S, Mandruzzato S, Lee HM, Seliger B,

Freedman RS, Taylor PR, Hu N, Zanovello P, Marincola FM and Wang E. Common Cancer Biomarkers.

Cancer Res, 66: (6). 2006.

9

53) Eleonora Aricò, Ena Wang, Maria Lina Tornesello, George K. Lewis, Francesco M. Marincola, Franco M.

Buonaguro, Luigi Buonaguro. Immature Monocyte Derived Dendritic Cells gene expression profile in

response to Virus-Like Particles stimulation. J Transl Med’ 2005, 3:45

54) Xin Li, Ena Wang, Ying-dong Zhao, Jia-Qiang Ren1, Ping Jin, Kai-Tai Yao and Francesco M Marincola.

Chromosomal imbalances in nasopharyngeal carcinoma: a meta-analysis of comparative genomic

hybridization results. J Transl Med 2006, 4:4

55) Jin P, Provenzano M, Deola S, Selleri S, Ren J, Voiculescu S, Stroncek D, Panelli MC, Marincola FM and

Wang E. Direct and indirect effects of interleukin-2 on peripheral blood mononuclear cells and T cell subsets –

J Transl Med, 2006, 4:26.

56) Wang X, Deavers M, Patenia R, Bassett Jr RL, Uueller P, Ma Q, Wang E and Freedman RS.

Monocyte/macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic

disease. J Transl Med 2006, 4:30.

57) Rossi L, Salvetti A, Marincola FM, Lena A, Deri P, Mannini L, Batistoni R, Wang E and Gremigni V.

Planarian stem cells: let’s have a squint at the neoblast gene expression profile. Genome Biol. 2007;8(4):R62

58) Ren J, Jin P, Wang E, Liu E, Li Xin, Marincola FM and Stroncek D. Pancreatic Islet Cell Therapy for Type I

Diabetes: Understanding the Effects of glucose stimulation on Islets in order to Produce Better Islets for

transplantation. J Transl Med, 2006.

59) Provenzano M, Salary Silvia, Wang E, Marincola FM, Stroncek D. Comprehensive epitope mapping of the

Epstein-Barr virus latent membrane protein-2 in ethnically diverse populations. Cancer Immunology

Immunotherapy 2007, 56(7):1047-63.

60) Deonarine K, Panelli, MC, Stashower ME, Jin P, Slade HB, Norwood C, Wang E, Marincola FM and

Stroncek DF. Gene expression profiling of cutaneous wound healing. J Transl Med, 2007 Feb 21;5:11

61) Li X, Ghandri N, Piancatelli D, Adams S, Wang E, Moncaco A, Bouaouina N, Stroncek D, Adorno D,

Chouchane L and Marincola FM. Associations between HLA and the prevalence of nasopharyngeal

carcinoma (NPC) among Tunisians. JTM, 2007, 5:22

62) Ren J, Jin P, Wang E, Liu E, Harlan DM, Li X and Stroncek DF. Pancreatic islet cell therapy for type I

diabetes: understanding the effects of glucose stimulation on islets in order to produce better islets for

transplantation. J Transl Med, 5:1 (03 Jan 2007).

63) Shin JW, Jin P, Fan Y, Slezak S, David-Ocampo V, Khuu H, Read E, Wang E, Marincola FM and Stroncek

D. Comparison of Immature Dendritic Cells Prepared from Fresh and 48-hour-stored Peripheral Blood

Mononuclear Cells. Transfusion. 2008;48(4):647-57.

64) Wang E, Selleri S and Marincola FM. The requirements for cytotoxic T cell (CTL)-mediated rejection of

cancer in humans: NKG2D and its role in the immune responsiveness of melanoma. Clinic Cancer Research,

2007, 13 (24): 7228-7231.

65) Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, Marincola FM and Szalay AA. Eradication of

Solid Human Breast Tumors in Nude Mice with an Intravenously Injected Light-Emitting Oncolytic

Vaccinia Virus. Cancer Res 2007 67: 10038-10046.

10

66) Buonaguro L, Monaco A, Arico E, Wang E, Tornesello ML, Lewis GK, Marincola FM and Buonaguro FM.

Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC

Bioinformatics, 2008, 26;9 Suppl 2:S5.

67) Jin P, Wang E, Ren J, Childs R, Shin JW, Khuu H, Marincola FM and Stroncek DF. Differentiation of two

types of mobilized peripheral blood progenitor cells by microRNA and cDNA expression analysis. JTM,

2008, 6:39.

68) Sabastino M, Zhao Y, Voiculescu S, Monaco A, Robbins P, Karai L, Nickoloff BJ, Maio M, Selleri S,

Marincola FM and Wang E. Conservation of genetic alterations in recurrent melanoma supports the

melanoma stem cell hypothesis. Cancer Research, 68(1):122-131, 2008

69) Deola S, Panelli MC, Maric D, Selleri S, Dmitrieva NI, Klein H, Stroncek D, Wang E and Marincola FM.

Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation

through CD27-CD70 interactions. The Journal of Immunology 180:1362-1372, 2008

70) Freedman FS, Wang E, Voiculescu S, Patenia R, Bassett RL, Deavers JM, Marincola FM and Newman RA.

Comparative Eicosanoid Levels and Gene Profiling in Ovarian Cancer and Benign Pelvic Disease. Clinic

Cancer Research, 2007, 13(19):5736-5744.

71) Shin JW, Jin P, Fan Y, Slezak S, David-Ocampo V, Khuu HM, Read EJ, Wang E, Marincola FM and

Stroncek DE. Evaluation of gene expression profiles of immature dendritic cells prepared from peripheral

blood mononuclear cells. Transfusion, 48: 647-657, 2008

72) Worschech A, Kmieciak M, Knutson KL, Bear HD, Szalay AA, Wang E, Marincola FM and Manjili MH.

Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res

2008, 68(7): 1-11

73) Freedman RS, Ma Q, Wang E, Gallardo ST,. Gordon IO, Shin J W, Jin P, Stroncek D and Marincola FM.

Migration Deficit in Monocyte-Macrophages in Human Ovarian Cancer. Cancer Immunol Immunother. 2008

May;57(5):635-45.

74) Selleri S, Deola S, Jin P, Pos Z, Slezak SL, Rumio C, Stroncek DE, Wang E and Marincola FM. GM-

CSF/IL-3/IL15 receptor common β chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T

cells. J Transl Med – 6 (1): 17, 2008

75) Selleri S, Palazzo M, Deola S, Wang E, Balsari A, Marincola FM and Rumio C. Induction of pro-

inflammatory programs in enteroendocrine cells by the Toll-like receptor agonists flagellin and bacterial

LPS. International Immunology 2008:1-10

76) Fang W, Li X, Jiang Q, Liu Z, Yang H, Liu Q, Wang S, Xie S, Liu T, Xie W, Huang J, Zhao Y, Wang E,

Marincola FM and Yao K. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal

carcinoma in Southern China. J Transl Med 2008, 6:32

77) Buonaguro L, Monaco A, Aricó E, Wang E, Tornesello ML, Lewis GK, Marincola FM and Buonaguro F.

Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC

Bioinformatics – 9 (s2): s5 RE, 2008

78) Nisticò P, Capone I, Palermo B, Del Bello D, Ferraresi V, Moschella F, Aricò, Valentini M, Bracci L,

Cognetti F, Ciccarese M, Vercillo G, Roselli M, Fossile E, Tosti ME, Wang E, Marincola F, Imberti L,

11

Natali PG, Belardelli F and Proietti E. Dacarbazine enhances vaccine-mediated antitumor immunity in

melanoma patients. Int J Cancer – 124: 130-139, 2008.

79) Sabatino M, Stroncek DF, Klein HG, Marincola FM and Wang E. Stem cells in melanoma development.

Cancer Letters 279 (2009) 119–125.

80) Worschech A, Kmieciak M, Keeler JM, Bear HD, Wang E, Marincola FM and Manjili MH. Signatures

associated with rejection or recurrence of HER-2/neu expressing mammary tumors describe the Yin and

Yang of tissue-specific destruction. Cancer Res 68: (7). April 1, 2008

81) Monaco A, Menolascina F, Zhoa Y, Tommasi S, Sabatino M, Fasano R, Paradiso A, Marincola FM and Wang

E. “Sequencing-grade” screening for BRCA-1 variants by oligo arrays. J Transl Med 2008, 6:64.

82) Donahue RE, Jin P, Bonifacino AC, Metzger ME, Ren J, Wang E, Stroncek DF. Plerixafor (AMD3100) and

granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global

gene and microRNA expression signatures. Blood. 2009 Sep 17;114(12):2530-41. Epub 2009 Jul 14.

83) Kaiser A, Paulos CM, Muranski P, Sanchez-Perez L, Heemskerk B, Wrzesinski C, Cassard L, Wang E, Liu

H, Marincola FM, Rosenberg SR and Restifo N. IL-17-producing CD8+ T cells can treat large established

tumors. Blood 2008, in press.

84) Sabatino M, Zhao Y, Voiculescu S, Monaco A, Robbins P, Karai L, Nickoloff BJ, Maio M, Selleri S,

Marincola FM, Wang E. Conservation of genetic alterations in recurrent melanoma supports the melanoma

stem cell hypothesis. Cancer Res. 2008 Jan 1;68(1):122-31.

85) Sabatino1 M, Kim-Schulze2 S, Panelli MC, Stroncek d, Wang E, Kim DW, Joshua Honeyman J, Pos Z,

Marincola FM and Kaufman HL. Serum vascular endothelial growth factor (VEGF) and fibronectin predict

clinical response to high-dose interleukin-2 (IL-2) therapy. JCO 2009:1-12. DOI:

10.1200/JCO.2008.19.1106

86) Ren J, Jin P, Wang E, Francesco FM and Stroncek DF. miRNA and gene expression patterns in the

differentiation of human embryonic stem cells. JTM 2009, 7:20. doi:10.1186/1479-5876-7-20.

87) Jin P, Wang E, Ren J, Childs C, Shin JW, Khuu H, Marincola FM and Stroncek DF. Differentiation of two

types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. JTM 6:39,

2008.

88) Selleri S, Palazzo M, Deola S, Wang E, Balsari A, Marincola FM and Rumio C. Induction of pro-

inflammatory programs in enteroendocrine cells by the Toll-like receptor agonists flagellin and bacterial

lipopolysaccharide. Int Immunol - 20(8): 961-70: 2008

89) Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW, de la Rocha P, Yang MY, Mok S,

Garban HJ, Craft N, Economou JS, Marincola FM, Wang E, Ribas A. Enhanced antitumor activity induced

by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res.

2009 Nov 15;69(22):8693-9. Epub 2009 Oct 27.

90) Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, Weibel S, Raab V, Sabatino M, Monaco A, Liu H, Buller

RM, Stroncek DF, Wang E, Szalay AA and Marincola FM. Systemic treatment of xenografts with vaccinia

virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics, 2009 Jul 7;10:301.

12

91) Li X, Fasano R, Wang E, Yao K and Marincola FM. HLA Associations with Nasopharyngeal Carcinoma

Curr Mol Med. 2009 Aug;9(6):751-65.

92) Slezak S, Jing P, Caruccio L, Ren J, Bennett M, Zia Nausheen, Adams S, Wang E, Ascensao J, Schechter G

and Stroncek D. Gene and micro RNA analysis of neutrophils from patients with polycythemia vera and

essential thrombocytosis: down-regulation of micro RNA-1 and 133a. JTM 2009 Jun 4;7:39.

93) Yang HL, Chen WQ, Cao X, Worschech A, Du LF, Fang WY, Xu YY, Stroncek DF, Li X, Wang E,

Marincola FM.. Caveolin-1 enhances resveratrol-mediated cytotoxicity and transport in a hepatocellular

carcinoma model. JTM 2009, 7:22. doi:10.1186/1479-5876-7-22

94) Seung-Jae Noh Samuel H. Mille,r Y.Terry Lee, Sung-Ho Goh, Francesco M. Marincola, David F. Stroncek,

Christopher Reed, Ena Wang, Jeffery L. Millel. Let-7 microRNAs are developmentally regulated in

circulating human erythroid cells. J Transl Med – 7(1): 98, 2009

95) Worschech A, Haddad D, Stroncek DF, Wang E, Marincola FM and Szalay AA. The immunologic aspects

of oncolytic therapy with poxviruses. Cancer Immunol Immunother – 58(9): 1355-1362, 2009

96) Jin P, Han TH, Ren J, Saunders S, Wang E, Marincola FM, Stroncek DF. Molecular signatures of maturing

dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med. 2010 Jan

15;8(1):4

97) Stroncek DF, Jin P, Wang E, Ren J, Sabatino M and Marincola FM. Global transcriptional analysis for

biomarker discovery and validation in cancer and hematological malignancies biologic therapies. Mol Diagn

Ther – 13 (3): 181-193, 2009

98) Monaco A, Marincola FM, Sabatino M, Pos Z, Tornesello ML, Stroncek DF, Wang E, Lewis GK,

Buonaguro FM, Buonaguro L. Molecular immune signatures of HIV-1 vaccines in human PBMCs. FEBS

Letters – 583: 3004-3008, 2009.

99) De Giorgi V, Monaco A, Worchech A, Tornesello M, Izzo F, Buonaguro L, Marincola FM, Wang E,

Buonaguro FM. Gene Profiling, biomarkers and pathways characterizing HCV-related hepatocellular

carcinoma – J Transl Med – 7: 85, 2009.

100) Jia S, Wang H, Wang RY, Wang E, Marincola FM, Alter HJ. Limitedly suppression of innate immune

responses induced by dsRNA and HCV positive ssRNA in HCV positive human hepatoma cells. In

preparation

101) De Giorgi V, Monaco A, Worchech A, Tornesello ML, Izzo F, Buonaguro L, Marincola FM, Wang E and

Buonaguro FM. Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular

carcinoma. J Transl Med. 2009 Oct 12;7:85

102) Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E,

Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Liu H, Marincola FM, Wang E,

Economou JS and Gomez-Navarro J. Dendritic cell vaccination combined with CTLA4 blockade in patients

with metastatic melanoma – Clin Cancer Res – 15 (19): 6267-6276, 2009.

103) Landi TM, ZhaoYD, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I,

Marincola FM, Tucker MA, Bertazzi PA, Pesatori AC, Caporaso NE, McShane LM and Wang E.

MicroRNA Expression Differentiates Histology and Predicts Survival of Lung Cancer. Clin Cancer Res;

16(2) January 15, 2010. AACR Journals most cited paper in 2010.

13

104) Bedognetti D, Wang E, Sertoli MR, and Marincola FM. Melanoma and biomarkers of

immunoresponsiveness: predicting the clinical outcome of immunotherapy. E-book: EMERGING

THERAPEUTICS FOR MELANOMA, edited by Prof. Francesco M Marincola & Dr Paolo A Ascierto.

2011

105) Pos Z, Selleri S, Spivey TL, Wang JK, Liu H, Worschech A, Sabatino M, Monaco A, Leitman SF, Falus A,

Wang E, Alter HJ, Marincola FM. Genomic scale analysis of racial impact on response to IFN alpha. Proc

Natl Acad Sci 107:803-808, 2010

106) Koshiol J, Wang E, Zhao Y, Marincola F, Landi MT. Strengths and limitations of laboratory procedures for

microRNA detection. Cancer Epidemiology, Biomarkers & Prevention 2010 Apr;19(4):907-11. Epub 2010

Mar 23

107) Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA, Martinson J, Lotze MT, Marincola

FM, Wang E, Fujita M, Okada H. miR-17-92 expression in differentiated T cells - implications for cancer

immunotherapy. J Transl Med. 2010 Feb 18;8(1):17.

108) Salcedo R, Worschech A, Cardone M, Jones Y, Gyulai Z, Dai R-M, Wang E, Ma W, Haines D, Ohuigin C,

Marincola FM and Trinchieri G – MyD88-mediated signaling prevents development of adenocarcinomas of the

colon via interleukin-18 – J Exp Med 2010. July 12 DOI:10.1084/jem.2010099

109) Seliger B, Jasinski S, Dressler SP, Marincola FM, Recktenwald CV, Wang E, Lichtenfels R. Linkage of

microRNA and proteome-based profiling data sets: A perspective for the priorization of candidate

biomarkers in renal cell carcinoma? J. Proteome Res. Dec 14th 2010

110) Wang E, Bussom S, Chen J, Quinn C, Bedognetti D, Lam W, Guan F, Jiang Z, Mark Y, Zhao Y, Stroncek

DF, White J, Marincola FM, Cheng YC. Interaction of a traditional Chinese medicine (PHY906) and CPT-11

on the inflammatory process in the tumor microenvironment. BMC Medical Genomics 2011, 4:38

doi:10.1186/1755-8794-4-38

111) Phyllus Y. Mong, Deborah G. Feng, Jennifer Xiao, Dorota Moroziewicz, Marianna Sabatino, Olivia Szulc,

Georges J. Samaha, Daewon Kim, Seunghee Kim-Schulze, Ena Wang, Francesco M. Marincola, Howard L.

Kaufman and Qin Wang. Interleukin-2 (IL-2)-induced early albumin uptake and barrier dysfunction in

human endothelial cells. Submitted.

112) Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto M.L, Engle A.M, Liu H., Camacho F.M,

Marincola F.M, Garrido F and Cabrera T – Regression of melanoma metastases after Immunotherapy is

associated with activation of antigen presentation and interferon-mediated rejection genes – Int J Cancer.

2012 Jul 15;131(2):387-95. doi: 10.1002/ijc.26471. Epub 2011 Nov 9

113) Zhao Y, Wang E, Liu H, Rotunno M, Koshiol J, Marincola FM, Landi MT and McShane LM – Evaluation of

normalization methods for two-channel microRNA microarrays. J Transl Med 2010 Jul 21;8:69

114) Rotunno M, Zhao Y, Bergen AW, Koshiol J, Burdette L, Rubagotti M, Linnoila RI, Marincola FM, Bertazzi

PA, Pesatori AC, Caporaso NE, McShane LM, Wang E, Landi MT.. Inherited polymorphisms in the RNA-

mediated interference machinery affect microRNA expression and lung cancer survival. British Journal of

Cancer (2010) 103, 1870–1874.doi:10.1038/sj.bjc.6605976

14

115) Weibel S, Raab V, Yu YA, Worschech A, Wang E, Marincola FM, Szalay AA. Viral-mediated oncolysis is

the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC

Cancer 2011, 11:68 doi:10.1186/1471-2407-11-68

116) Castiello L, Stroncek DF, Finn MW, Wang E, Marincola FM, Clayberger C, Krensky AM, Sabatino M. 15

kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the

transcriptome level. Journal of Translational Medicine 2011, 9:41 (18 April 2011)

117) Kmieciak M, Payne KK, Idowu MO, Grimes MM, Graham L, Ascierto ML, Wang E, Wang XY, Bear HD,

Manjili MH. Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure.

Journal of Translational Medicine 2011, 9:35

118) Arico E, Castiello L, Urbani F, Rizza P, Panelli MC, Wang E, Marincola FM, Belardelli F. Concomitant

detection of IFNalpha signature and activated monocyte/dendritic cell precursors in the peripheral blood of

IFNalpha-treated subjects at early times after repeated local cytokine treatments. Journal of Translational

Medicine 2011, 9:67 (17 May 2011)

119) Seliger B, Dressler SP, Massa C, Recktenwald CV, Altenbernd F, Bukur J, Marincola FM, Wang E,

Stevanovic S and Lichtenfels R – Identification and characterization of human leukocyte antigen class I

ligands in renal cell carcinoma cells – Proteomics 2011, 11, 2528–2541

120) Respa A, Bukur J, Ferrone S, Pawelec G, Zhao Y, Wang E, Marincola FM, Seliger B. Association of IFN-

{gamma} Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell

Lines. Clin Cancer Res. 2011 May 1;17(9):2668-2678. Epub 2011 Jan 19

121) Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, Leonardi AJ, Morgan RA, Wang

E, Marincola FM, Trinchieri G, Rosenberg SA, Restifo NP. IL-12 triggers a programmatic change in

dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest. 2011 Nov 7. pii: 58814. doi:

10.1172/JCI58814.

122) Buonaguro L, Wang E, Tornesello ML, Buonaguro FM, Marincola FM. Systems biology applied to vaccine

and immunotherapy development. BMC Syst Biol. 2011 Sep 20;5(1):146.

123) Spivey TL, Uccellini L, Ascierto ML, Zoppoli G, De Giorgi V, Delogu LG, Engle AM, Thomas JM, Wang

E, Marincola FM and Bedognetti D. Gene expression profiling in acute allograft rejection: challenging the

immunologic constant of rejection hypothesis. Journal of Translational Medicine 2011, 9:174

124) Ascierto ML, de Giorgi V, Liu Q, Bedognetti D, Spivey T, Murtas D, Stroncek DF, Chouchane L, Manjili

M, Wang E, Marincola FM – An immunologic portrait of cancer – Journal Transl Med – 9: 146, 2011

125) Koshiol J, Gulley ML, Zhao Y, Rugobatti M, Marincola FM, Rotunno M, Tang W, Bergen AW, Bartazzi

pA, Roy D, Pesatory AC, Linnoila I, Dittmer D, Goldstein AM, Caporaso NE, McShane LM, Wang E and

Landi MT – Epstein-Barr virus microRNAs and lung cancer. British J Cancer – 105(2): 320-6; 2011

126) Wang E, Bussom S, Chen J, Quinn C, Bedognetti D, Lam W, Guan F, Jiang Z, Mark Y, Zhao Y, Stroncek

DF, White J, Marincola FM and Cheng Y-C – Interaction of a traditional Chinese Medicine (PHY906) and

CPT-11 on the inflammatory process in the tumor microenvironment – BMC Medical Genomics, 4: 38, 2011

127) Kmieciak M, Worschech A, Nikizad H, Gowda M, Habibi M, Depcrynski A, Wang E, Godder K, Holt SE,

Marincola FM and Manjili MH. CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the

priming phase of immune responses against breast cancer – Breast Cancer Res Treat – 126(2):385-94, 2011

15

128) Spivey TL, De Giorgi V, Zhao Y, Bedognetti D, Pos Z, Liu Q, Tomei S, Ascierto ML, Uccellini L,

Chouchanne L, Stroncek DF, Wang E and Marincola FM – The stable traits of melanoma genetics: an

alternate approach to target discovery. BMC Genomics – 13: 156; 2012

129) Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su Y,

Essenburg C, Kaufan D, DeKoning T, Enter MA, O’Rourke T, Marincola FM and Vande Woude GF – HGF-

autocrine activation predicts sensitivity to MET inhibition in glioblastoma – Proc Natl Acad Sci – 109 (2):

570-575, 2012

130) Scott CD, Klebanoff CA, Roychoudhuri R, Borman ZA, Marincola FM, Wang E, Yu Z, Palmer DC,

Gattinoni L, Rosenberg SA, and Restifo NP. An interaction of naïve and memory CD8+ T cells disrupts the

superior antitumor function of naïve cells. Submitted 2012

131) Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C,

Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP. A human memory T cell

subset with stem cell-like properties. Nat Med. 2011 Sep 18. doi: 10.1038/nm.2446

132) Castiello L, Stroncek DF, Finn MW, Wang E, Marincola FM, Clayberger C, Krensky AM, Sabatino M. 15

kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the

transcriptome level. J Transl Med. 2011 Apr 18;9:41

133) Ji Y, Pos Z, Rao M, Klebanoff CA, Yu Z, Sukumar M, Reger RN, Palmer DC, Borman ZA, Muranski P,

Wang E, Schrump DS, Marincola FM, Restifo NP, Gattinoni L. Repression of the DNA-binding inhibitor

Id3 by Blimp-1 limits the formation of memory CD8(+) T cells. Nat Immunol. 2011 Nov 6;12(12):1230-7.

doi: 10.1038/ni.2153

134) Gowda M, Godder K, Kmieciak M, Worschech A, Ascierto ML, Wang E, Marincola FM, Manjili MH.

Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. J Transl Med. 2011

Oct 6;9:170.

135) Ascierto ML, Kmieciak M, Idowu MO, Grimes M, Dumur C, Wang E, Demur C, Bear HD, Marincola FM

and Manjili MH - A signature of immune function genes associated with recurrence-free survival in breast

cancer patients – Breast Cancer Res Treat. 2012 Feb;131(3):871-80. Epub 2011 Apr 11.

136) Bedognetti D, Sertoli MR, Pronzato P, Del Mastro L, Venturini M, Taveggia P, Zanardi E, Siffredi G,

Pastorino S, Queirolo P, Gardin G, Wang E, Monzeglio C, Boccardo F, Bruzzi P. Concurrent versus

Sequential Adjuvant Chemo-Hormone Therapy in Breast Cancer: A Multi-center, Randomized, Phase III

Trial. J Natl Cancer Inst. 2011 Oct 19;103(20):1529-39. Epub 2011 Sep 15.

137) Ascierto ML, Worschech A, Yu Z, Adams S, Reinboth J, Chen NG, Pos Z, Roychoudhuri R, Di Pasquale G,

Bedognetti D, Uccellini L, Rossano F, Ascierto PA, Stroncek DF, Restifo NP, Wang E, Szalay AA and

Marincola FM – Permissivity of the NCI-60 cancer cell lines to oncolytic vaccinia virus GLV-1h68 – BMC

Cancer 11: 451, 2011.

138) Gowda M, Godder K, Kmieciak M, Worschech A, Ascierto ML, Wang E, Marincola FM and Manjili MH –

The pattern of the immune response differs in low-risk vs high risk neuroblastoma – J Transl Med 9:170,

2011

139) Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su Y,

Essenburg C, Kaufman DW, DeKoning T, Enter MA, O'Rourke TJ, Marincola FM, Vande Woude GF.

16

HGF-autocrine Activation Predicts Sensitivity to MET Inhibition in Glioblastoma. Proc Natl Acad Sci U S

A. 2012 Jan 10;109(2):570-5. Epub 2011 Dec 27.

140) Uccellini L, Tseng FC, Monaco A, Shebl FM, Pfeiffer R, Dotrang M, Buckett D, Busch MP, Wang E, Edlin

BR, Marincola FM, O'Brien TR. HCV RNA Levels in a Multi-Ethnic Cohort of Injection Drug

Users:Human Genetic, Viral and Demographic Associations. Hepatology. 2012 Jul;56(1):86-94. doi:

10.1002/hep.25652. Epub 2012 Jun 1.

141) Shan J, Dsousza SP, Bakhru S, Al-Azwani EK, Ascierto ML, Sastry KS, Bedri S, Kizhakayil D, Aigha II,

Malek J, Al-Bozom I, Gehani S, Furtado S, Mathiew E, Wang E, Marincola FM, Chouchane L. TNRC9

downregulates BRCA1 expression and promotes breast cancer aggressiveness. Cancer Res. 2013 Feb 27.

142) Wang E, Zhao Y, Monaco A, Uccellini L, Kirkwood JM, Spyropoulou-Vlachou M, Panelli MC, Marincola

FM, Gogas H. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients

receiving adjuvant interferon. PloOne, 2012, 7 (7):e40805.

143) Longo DM, Louie B, Mathi K, Pos Z, Wang E, Hawtin RE, Marincola FM, and Cesano A. Racial

differences in B cell receptor signaling pathway activation. J Transl Med. 2012 Jun 6;10(1):113

144) Longo DM, Louie B, Putta S, Evensen E, Ptacek J, Cordeiro J, Wang E, Pos Z, Hawtin RE, Marincola FM,

Cesano A. Single-cell network profiling of peripheral blood mononuclear cells from healthy donors reveals

age- and race-associated differences in immune signaling pathway activation. J Immunol. 2012 Feb

15;188(4):1717-25. Epub 2012 Jan 13.

145) Longo DM, Louie B, Ptacek J, Friedland G, Evensen E, Putta S, Atallah M, Spellmeyer D, Wang E, Pos Z,

Marincola FM, Schaeffer A, Lukac S, Railkar R, Beals CR, Cesano A, Carayannopoulos LN, Hawtin RE.

High-dimensional analysis of the aging immune system: verification of age-associated differences in

immune signaling responses in healthy donors. J Transl Med. 2014 Jun 21;12:178. doi: 10.1186/1479-5876-

12-178.

146) Longo DM, Louie B, Wang E, Pos Z, Marincola FM, Hawtin RE, Cesano A. Inter-donor variation in cell

subset specific immune signaling responses in healthy individuals. Am J Clin Exp Immunol. 2012 Apr

24;1(1):1-11. Print 2012.

147) Unlu S, Tang S, Wang E, Martinez I, Tang D, Bianchi ME, Zeh HJ 3rd, Lotze MT. Damage ass 1 ociated

molecular pattern molecule-induced microRNAs (DAMPmiRs) induction in human peripheral blood

mononuclear cells. PLoS ONE. 2012; vol. 7(6) pp. e38899

148) Bedognetti D, Spivey TL, Uccellini L, WangE , Dudley ME, Zhao Y, Ascierto ML, De Giorgi V, Tomei S,

Liu Q, Sertoli MR, Marincola FM, and Rosenberg SA. CXCR3 and CCR5 polymorphism, gene and protein

expression as biomarkers of responsiveness to adoptive therapy in metastatic melanoma patients. British

Journal of Cancer (2013) 109, 2412–2423 | doi: 10.1038/bjc.2013.557

149) Uccellini L, De Giorgi V, Zhao Y, Tumaini B, Erdenebileg N, Dudley ME, Tomei S, Bedognetti D, Ascierto

ML, Liu Q, Simon R, Kottyan L, Kaufman KM, Harley JB, Wang E, Rosenberg SA, Marincola FM. IRF5

gene polymorphisms in melanoma. Journal of Translational Medicine 2012, 10:170

150) Sukumar M, Liu L, Quijano C, Ji Y, Karoly ED, Mahoney R, Yu Z, Wang E, Leonardi A, Klebanoff CA,

Palmer DA, Muranski P, Roychoudhuri R, Franco Z, Marincola FM, Finkel T, Restifo NP and Gattinoni L.

mTOR regulates CD8+ memory T cell differentiation by modulating glycolysis but not fatty acid

metabolism. Submitted to Nature Med. 2012

17

151) Tomei S, Adams S, Uccellini L, Bedognetti D, De Giorgi V, Erdenebileg N, Ascierto ML, Reinboth J, Liu

Q, Bevilacqua G, Wang E, Mazzanti C, Marincola FM. Association between HRAS rs12628 and

rs112587690 polymorphisms with the risk of melanoma in the North American population. Med Oncol. 2012

May 22 published online, DOI 10.1007/s12032-012-0255-3.

152) Lam TK, Shao S, Zhao Y, Marincola FM, Pesatori A, Bertazzi PA, Caporaso NE, Wang E and Landi MT –

Influence of quercitin-rich food intake on microRNA expression in lung cancer. Cancer Epidemiol

Biomarkers Prev. 2012 Dec;21(12):2176-84.

153) Petrizzo A, Tornesello ML, Napolitano M, D’Alessio G, Megna AS, Dolcetti R, De Re V, Wang E,

Marincola FM, Buonaguro FM and Buonaguro L – Multiparametric analyses of human PBMCs loaded ex

vivo with a candidate idiotype vaccine for HCV-related lymphoproliferative disorders. PLoS One.

2012;7(9):e44870.

154) Reinboth J, Ascierto ML, Chen NG, Zhang Q, Yu YA, Aguilar RJ, Carretero R, Worschech A, Zhao Y,

Wang E, Marincola FM and Szalay AA – Correlates between host and viral transcriptional program

associated with different oncolytic vaccinia virus isolates. Hum Gene Ther Methods. 2012 Oct;23(5):285-96.

155) Castiello L, Sabatino M, Zhao Y, Trishman T, Tumaini B, Ren J, Jin P, Wang E, Marincola FM, Puri RK,

Stroncek DF. Characterization of cellular immunotherapies: rapid assessment of quality controls and markers

for clinical grade cellular immunotherapies. Mol Ther. 2013 Feb;21(2):476-84. doi: 10.1038/mt.2012.89.

Epub 2012 Nov 13.

156) De Giorgi V, Buonaguro L, Worschech A, Tornesello ML, Izzo F, Marincola FM, Wang E and Buonaguro

FM – Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis-

PloS ONE – 8 (2): e56153, 2013

157) Xiaoming Lu, Longmei Cai, Yanfeng Ye, Lan Zhang, Cuncun Yuan, Weiren Luo, Minghui Yang, Hang

Zeng, Yaoyong Lu, Yi Deng, Ying he, Ena Wang, Francesco M. Marincola, Kaitai Yao, Weiyi Fang,

Hongbing Cai, Xin Li. Low TGFβR2 expression is an unfavorable prognostic factor, modulated by hsa-miR-

93 or hsa-miR-20a, and accompanied by PI3K/Akt activation in aggressive Nasopharyngeal Carcinoma.

Submitted, 2013

158) Yanfen Ye, Longmei Cai, Xaioming Lyu, Cuncun Yuan, Hang Zeng , Ying Wang, Yuxiang Chen, Yaoyong

Lu, Yi Deng , Lan Zhang, Shuang Wang, Tengfei Liu, , Ying he , Zhen Liu, Ena Wang, Francesco M.

Marincola, Kaitai Yao, Weiyi Fang, Hongbing Cai, Xin Li. EBV-miR-BART1 promotes nasopharyngeal

carcinoma progression through regulating tumor suppressor PTEN and its downstream signals. PloS

Pathogens, submitted. 2013

159) Zhang L, Alter HJ, Wang H, Jia S, Wang E, Marincola FM, Shih JW, Wang RY. The Modulation of

Hepatitis C Virus 1a Replication by PKR is Dependent on NF-kB Mediated Interferon Beta Response in

Huh7.5.1 Cells. Virology. 2013 Mar 30;438(1):28-36.

160) Tomei S, Adams S, Uccellini L, Bedognetti D, De Giorgi V, Erdenebileg N, Ascierto ML, Reinboth J, Liu

Qiuzhen, Bevilacqua G, Wang E, Mazzanti C and Marincola FM – Association between HRAS rs12628 and

re112587690 polymorphisms with the risk of melanoma in the North American population. Med Oncol. 2012

Dec;29(5):3456-61.

161) Sonda N, Simonato F, Peranzoni E, Calì B, Bortoluzzi S, Bisognin A, Wang E, Marincola FM, Naldini L,

Gentner B, Trautwein C, Sackett SD, Zanovello P, Molon B, Bronte V.. miR-142-3p prevents macrophage

18

differentiation during cancer-induced myelopoiesis. Immunity. 2013 Jun 27;38(6):1236-49. doi:

10.1016/j.immuni.2013.06.004.

162) Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang XY, Dumur CI, Bedognetti D, Tomei S,

Ascierto PA, Shanker A, Bear HD, Wang E, Marincola FM, De Maria A, Manjili MH. Molecular signatures

mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl

Med. 2013 Jun 12;11:145. doi: 10.1186/1479-5876-11-145.

163) Pos Z, Spivey TL, Liu H, Sommariva M, Chen J, Wunderlich JR, Parisi G, Tomei S, Ayotte BD, Stroncek

DF, Malek JA, Robbins PF, Rivoltini L, Maio M, Chouchane L, Wang E, Marincola FM. Longitudinal

study of recurrent metastatic melanoma underscores the individuality of cancer Biology. J Invest Dermatol.

2014 May;134(5):1389-96. doi: 10.1038/jid.2013.495. Epub 2013 Nov 22.

164) Biancotto A, Wank A, Perl S, Cook W, Olnes MJ, Dagur PK, Fuchs JC, Langweiler M, Wang E, McCoy JP.

Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjects.

PLoS One. 2013 Dec 12;8(12):e76091. doi: 10.1371/journal.pone.0076091. eCollection 2013

165) Ileana S Mauldin, Ena Wang, Donna H Deacon, Walter C Olson, Yongde Bao, Craig L Slingluff. TLR2/6

agonists and interferon-gamma induce human melanoma cells to produce CXCL10: TLR2/6 agonists and

IFNγ induce CXCL10 from melanoma. International Journal of Cancer 03/2015; DOI:10.1002/ijc.29515 ·

5.01 Impact Factor

166) Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T,

Cramer S, Dai RM, Kiu H, Cardone M, Naik S, Patri AK, Wang E, Marincola FM, Frank KM, Belkaid Y,

Trinchieri G, Goldszmid RS. Commensal bacteria control cancer response to therapy by modulating the

tumor microenvironment. Science. 2013 Nov 22;342(6161):967-70. doi: 10.1126/science.1240527.

167) Petrizzo A, Tornesello ML, Napolitano M, D'Alessio G, Salomone Megna A, Dolcetti R, De Re V, Wang E,

Marincola FM, Buonaguro FM, Buonaguro L. Multiparametric analyses of human PBMCs loaded ex vivo

with a candidate idiotype vaccine for HCV-related lymphoproliferative disorders. PLoS One.

2012;7(9):e44870.

168) Kerkar SP, Chinnasamy D, Hadi N, Melenhorst J, Muranski P, Spyridonidis A, Ito S, Weber G, Yin F,

Hensel N, Wang E, Marincola FM, Barrett AJ. Timing and intensity of exposure to Interferon-gamma

critically determines T cell stimulatory function of monocyte-derived dendritic cells. Immunology. 2014

Sep;143(1):96-108. doi: 10.1111/imm.12292.

169) Ito S, Bollard C, Carlsten M, Melenhorst J, Biancotto A, Wang E, Chen J, Kotliarov Y, Cheung F, Xiw Z,

Marincola F, Tanimoito K, Battiwalla M, Olnes M, Perl S, Shum P, Hughes T, Keyvanfar K, Hensel N,

Muranski P, Young N, Barrett A. Ultra-low dose interlukin-2 promotes immune-modulating function of

regulatory T cells and natural killer cells in healthy volenteers” Mol Ther – 2014 Jul;22(7):1388-95. doi:

10.1038/mt.2014.50. Epub 2014 Apr 1

170) Thomas JM, Pos Z, Reinboth J, Wang RY, Wang E, Frank GM, Lusso P, Trinchieri G, Alter HJ, Marincola

FM, Thomas E. Differential responses of plasmacytoid dendritic cells to influenza virus and distinct viral

pathogens. J Virol. 2014 Sep;88(18):10758-66. doi: 10.1128/JVI.01501-14.

171) Kapanadze T1, Medina-Echeverz J, Gamrekelashvili J, Weiss JM, Wiltrout RH, Kapoor V, Hawk N, Terabe

M, Berzofsky JA, Manns MP, Wang E, Marincola FM, Korangy F, Greten TF. Tumor-induced CD11b(+)

19

Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-

dependent manner. Eur J Immunol. 2015 Apr;45(4):1148-58. doi: 10.1002/eji.201445093. Epub 2015 Feb

23.

172) Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio

M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-

Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G,

Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang

E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research. Meeting

report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”. J Transl Med. 2013 Jun 3;11:137

173) Murtas D, Maric D, De Giorgi V, Reinboth J, Worschech A, Fetsch P, Filie A, Ascierto ML, Bedognetti D,

Liu Q, Uccellini L, Chouchane L, Wang E, Marincola FM, Tomei S. IRF-1 responsiveness to IFN-γ predicts

different cancer immune phenotypes. Br J Cancer. 2013 Jul 9;109(1):76-82.

174) Chiara Massa, Carolin Thomas, Ena Wang, Francesco Marincola, Barbara Seliger. Different maturation

cocktails provide dendritic cells with different chemoattractive properties. Journal of Translational Medicine

12/2015; 13 Suppl 1(1):175. DOI:10.1186/s12967-015-0528-7 · 3.99 Impact Factor

175) Ascierto ML, Bozzano F, Bedognetti D, Marras F, Schechterly C, Matsuura K, Picciotto A, Marenco S, Zhao

Y, DeGiorgi V, Sommariva M, Moretta L, Wang E, Alter HJ, Marincola FM, De Maria A. Inherent

transcriptional profile of Natural Killer cells is associated with treatment outcome of chronic HCV infection.

J Transl Med. 2015 Mar 1;13:77. doi: 10.1186/s12967-015-0428-x.

176) Petrizzo A, Tornesello ML, Napolitano M, D'Alessio G, Salomone Megna A, Dolcetti R, De Re V, Wang E,

Marincola FM, Buonaguro FM, Buonaguro L. Multiparametric analyses of human PBMCs loaded ex vivo

with a candidate idiotype vaccine for HCV-related lymphoproliferative disorders. PLoS One. 2012;7(9)

177) Crende O, Sabatino M, Valcárcel M, Carrascal T, Riestra P, López-Guerrero JA, Nagore E, Mandruzzato S,

Wang E, Marincola FM, Vidal-Vanaclocha F. Metastatic lesions with and without interleukin-18-dependent

genes in advanced-stage melanoma patients. Am J Pathol. 2013 Jul;183(1):69-82

178) Dickler HB, McCoy JP, Nussenblatt R, Perl S, Schwartzberg PA, Tsang JS, Wang E, Young NS. The

National Institutes of Health Center for Human Immunology, Autoimmunity, and Inflammation: history and

progress. Ann N Y Acad Sci. 2013 May;1285:133-47

179) Yu X, Zhen Y, Yang H, Wang H, Zhou Y, Wang E, Marincola FM, Mai C, Chen Y, Wei H, Song Y, Lyu X,

Ye Y, Cai L, Wu Q, Zhao M, Hua S, Fu Q, Zhang Y, Yao K, Liu Z, Li X, Fang W. Loss of connective tissue

growth factor as an unfavorable prognosis factor activates miR-18b by PI3K/AKT/C-Jun and C-Myc and

promotes cell growth in nasopharyngeal carcinoma. Cell Death Dis. 2013 May 16;4:e634. doi: 10.1038/cddis

180) Tsang JS, Schwartzberg PL, Kotliarov Y, Biancotto A, Xie Z, Germain RN, Wang E, Olnes MJ, Narayanan

M, Golding H, Moir S, Dickler HB, Perl S, Cheung F; Baylor HIPC Center; CHI Consortium. Global

analyses of human immune variation reveal baseline predictors of the post‐vaccination response. Cell. 2014

Apr 10;157(2):499-513. doi: 10.1016/j.cell.2014.03.031..

181) Ascierto PA, Grimaldi AM, Anderson A, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M,

Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi F, Kefford R, Kirkwood JM, Larkin J,

Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling

B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin

20

M. Future perspectives in melanoma research: meeting report from the ¿Melanoma Bridge¿, Napoli,

December 5th-8th 2013. J Transl Med. 2014 Oct 28;12(1):277

182) Matthew J Olnes, Yuri Kotliarov, Angelique Biancotto, Foo Cheung, Ena Wang, John S Tsang, and Robert

Nussenblatt, and the CHI Consortium. Effects of Systemically Administered Hydrocortisone on the Human

Immunome. Submitted

183) Christopher A. Klebanoff, Christopher D. Scott, Anthony J. Leonardi, Madhu Ramaswamy, Anthony C.

Cruz, Tori Yamamoto, Rahul Roychoudhuri, Yun Ji, Madhu Sukumar, Douglas C. Palmer, Zachary A.

Borman, Joseph G. Crompton, David Clever, Zhiya Yu, Hui Liu, Ena Wang, Francesco M. Marincola,

Luca Gattinoni, Steven A. Rosenberg, Richard M. Siegel, Nicholas P. Restifo. Memory CD8+ T cells induce

precocious effector differentiation of naïve T cells through quorum sensing-like behavior. Submitted.

184) Bedognetti D, Wang E, Marincola FM. Meta-analysis and metagenes: CXCL-13-driven signature as a robust

marker of intratumoral immune response and predictor of breast cancer chemotherapeutic outcome.

Oncoimmunology. 2014 Apr 9;3:e28727. eCollection 2014.

185) Acquavella N, Clever D, Yu Z, Roelke-Parker M, Palmer DC, Xi L, Pflicke H, Ji Y, Gros A, Hanada

KI, Goldlust I, Mehta G, Klebanoff CA, Crompton JG, Sukumar M, Morrow JJ, Franco Z, Gattinoni L, Liu

H, Wang E, Marincola FM, Stroncek DF, Lee CC, Raffeld M, Bosenberg MW, Roychoudhuri R, Restifo

NP.Type1 cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol

Res. 2014 Oct 30. pii: canimm.0122.2014.

186) Caputo E, Wang E, Valentino A, Crispi S, De Giorgi V, Fico A, Ficili B, Capone M, Anniciello A,

Cavalcanti E, Botti G, Mozzillo N, Ascierto P, Marincola FM and Travali S – Ran signaling in melanoma:

implications for the development of alternative therapeutic strategies – Cancer Lett – 2015 Feb

1;357(1):286-96. doi: 10.1016/j.canlet.2014.11.033.

187) Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang

L, Wang E, Marincola FM, Bedognetti D, Powell DJ Jr, Tanyi J, Feldman MD, Kandalaft LE, Coukos G.

The Ovarian Cancer Chemokine Landscape is Conducive to Homing of Vaccine-primed and CD3/CD28

Costimulated T cells Prepared for Adoptive Therapy. Clinical Cancer Research 02/2015; 21(12).

DOI:10.1158/1078-0432.CCR-14-2777 · 8.19 Impact Factor

188) Jennifer Reinboth, Valeria De Giorgi, Maria L Ascierto, Sara Tomei, Nanhai G Chen, Mehmet O Kilinc,

Barbara Tumaini, Lorenzo Uccellini, Ena Wang, Dragan Maric, Francesco M Marincola, Aladar A Szalay.

Cellular Parameters Related to Permissiveness to Oncolytic Vaccinia Virus Replication in Melanoma

Derived Cell Cultures. Submitted. 2014

189) Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, Tran E, Hanada K, Yu Z, Palmer

DC, Kerkar SP, Michalek RD, Upham T, Leonardi A, Acquavella N, Wang E, Marincola FM, Gattinoni L,

Muranski P, Sundrud MS, Klebanoff CA, Rosenberg SA, Fearon DT, Restifo NP. Akt inhibition enhances

expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 2015 Jan

15;75(2):296-305. doi: 10.1158/0008-5472.CAN-14-2277. Epub 2014 Nov 28.

190) Cara L. Haymaker, Richard C. Wu, Krit Ritthipichai, Chantale Bernatchez, Marie-Andrée Forget, Jie Qing

Chen, Hui Liu, Ena Wang, Francesco Marincola, Patrick Hwu, Laszlo G. Radvanyi. BTLA marks a less-

differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties.

OncoImmunology 05/2015; DOI:10.1080/2162402X.2015.1014246 · 6.28 Impact Factor

21

191) Forget MA, Malu S, Liu H, Toth C, Maiti S, Kale C, Haymaker C, Bernatchez C, Huls H, Wang E,

Marincola FM, Hwu P, Cooper LJ, Radvanyi LG. Activation and propagation of tumor-infiltrating

lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of

melanoma. J Immunother. 2014 Nov-Dec;37(9):448-60. doi: 10.1097/CJI.0000000000000056.

192) Sastry KS, Al-Muftah MA, Li P, Al-Kowari MK, Wang E, Ismail Chouchane A, Kizhakayil D, Kulik

G, Marincola FM, Haoudi A, Chouchane Targeting proapoptotic protein BAD inhibits survival and self-

renewal of cancer stem cells. Cell Death Differ. 2014 Dec;21(12):1936-49. doi: 10.1038/cdd.2014.140.

193) Comertpay S, Pastorino S, Tanji M, Mezzapelle R, Strianese O, Napolitano A, Baumann F, Weigel T,

Friedberg J, Sugarbaker P, Krausz T, Wang E, Powers A, Gaudino G, Kanodia S, Pass HI, Parsons BL,

Yang H, Carbone M. Evaluation of Clonal Origin of Malignant Mesothelioma. J Transl Med. 2014 Dec

4;12:301. doi: 10.1186/s12967-014-0301-3.

194) Leisz S, Schulz K, Erb S, Oefner P, Dettmer K, Mougiakakos D, Wang E, Marincola FM, Stehle F, Seliger

B. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression

patterns of renal cell carcinoma using ome-based strategies and their effects on the cellular metabolism.

Oncotarget. 2015 May 10;6(13):11395-406. 6.63 Impact Factor

195) Pablo Saenz-Lopez, Jennifer Reinboth, Hernani Gil, Davide Bedognetti, Rafael Carretero, Jose Manuel

Cozar, Francesco M. Marincola, Federico Garrido, Ena Wang and Teresa Cabrera. Comparative gene

expression analysis of genes associated with T cells subsets in bladder tumors treated with BCG: Association

with cancer recurrence. In preparation.

196) Liu Q, Tomei S, Ascierto ML, De Giorgi V, Bedognetti D, Dai C, Uccellini L, Spivey T, Pos Z, Thomas J,

Reinboth J, Murtas D, Zhang Q, Chouchane L, Weiss GR, Slingluff CL Jr, Lee PP, Rosenberg SA, Alter H,

Yao K, Wang E, Marincola FM. Melanoma NOS1 expression promotes dysfunctional IFN signaling. J Clin

Invest. 2014;124(5):2147–2159. doi:10.1172/JCI69611.

197) Acquavella N, Clever D, Yu Z, Roelke-Parker M, Palmer DC, Xi L, Pflicke H, Ji Y, Gros A, Hanada K,

Goldlust IS, Mehta GU, Klebanoff CA, Crompton JG, Sukumar M, Morrow JJ, Franco Z, Gattinoni L, Liu

H, Wang E, Marincola F, Stroncek DF, Lee CC, Raffeld M, Bosenberg MW, Roychoudhuri R, Restifo NP.

Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol Res.

2015 Jan;3(1):37-47. doi: 10.1158/2326-6066.CIR-14-0122. Epub 2014 Oct 30.

198) Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, Sciumè G, Zare H, Vahedi

G, Dema B, Yu Z, Liu H, Takahashi H, Rao M, Muranski P, Crompton JG, Punkosdy G, Bedognetti D,

Wang E, Hoffmann V, Rivera J, Marincola FM, Nakamura A, Sartorelli V, Kanno Y, Gattinoni L, Muto A,

Igarashi K, O'Shea JJ, Restifo NP. BACH2 represses effector programs to stabilize T(reg)-mediated immune

homeostasis. Nature. 2013 Jun 27;498(7455):506-10. doi: 10.1038/nature12199. Epub 2013 Jun 2.

199) Kapenadze T, Medina-Echeverz J, Gamrekelashvili J, Weiss JM, Wiltrout RH, Kapoor V, Hawk N, Terabe

M, Berzofski JA, Manns MP, Wang E, Marincola FM, Korangy F, Greten TF – Tumor-induced CD11b+Gr-

1+ myeloid-derived suppressor cells exacerbate immune mediated hepatitis in mice in a CD40-dependent

manner – Eur J Immunol. 2015 Apr;45(4):1148-58. doi: 10.1002/eji.201445093.

200) Tomei S, Bedognetti D, De Giorgi V, Sommariva M, Civini S, Reinboth J, Al Hashmi M, Ascierto ML, Liu Q,

Ayotte B, Worschech A, Ucellini L, Ascierto P, Stroncek D, Palmieri G, Chouchane L, Wang E and Marincola

FM – The immune-related role of BRAF in melanoma – Mol Oncol. 2015 Jan;9(1):93-104. doi: 10.1016

22

201) Yadav SK, Rizwan A, Singh A, Cai K, Kaura D, Wang E, Davatzikos C, Trojanowski JQ, Melhem ER,

Marincola FM, Borthakur A, M Haris - T1rho MRI and CSF biomarkers in the diagnosis of Alzheimer’s

disease – Neuroimage Clin – 7: 598-604, 2015.

202) Cai LM, Lyu XM, Luo WR, Cui XF, Ye YF, Yuan CC, Peng QX, Wu DH, Liu TG, Wang E, Marincola FM,

Yao KT, Fang WY, Cai HB, Li X – EBV-mir-BART7-3p promoted the EMT and metastatis of nasopharyngeal

carcinoma cell by suppressing the tumor suppressor PTEN – Oncogene – Oncogene. 2015 Apr 23;34(17):2156-

66. doi: 10.1038/onc.2014.341.

203) Tomei S, Mamtani R, Al Ali R, Elkum N, Abdulmalik M, Ismail A, Cheema S, Rouh HA, Aigha II, Hani F,

Al-Samraye S, Taher Aseel M, Al Emadi N, Al Mujalli A, Abdelkerim A, Youssif S, Worshech A, El

Sebakhy E, Temanni R, Khanna V, Wang E, Kizhkayil D, Al-Thank M, Lowenfels A, Marincola FM,

Sheikh J, Chouchanne L - Obesity susceptibility loci in Qataris, a highly consanguineous Arabian population

– J Transl Med 13: 119, 2015.

204) Crompton JG, Narayanan M, Cuddapah S, Roychoudhuri R, Ji Y, Yang W, Patel SJ, Sukumar M, Palmer

DC, Peng W, Wang E, Marincola FM, Klebanoff CA, Zhao K, Tsang JS, Gattinoni L, Restifo NP – Lineage

relationship of CD8_ T cell subsets is revealed by progressive changes in the epigenetic landscape. Cellular

& molecular immunology 04/2015; DOI:10.1038/cmi.2015.032 · 4.19 Impact Factor

205) Simon Jasinski-Bergner, Adi Reches, Christine Stoehr, Juergen Bukur, Chiara Massa1, Verena Spath,

Roland Wartenberg, Helge Taubert4, Sven Wach, Bernd Wullich4, Ena Wang, Francesco M.

Marincola, Arndt Hartmann, Ofer Mandelboim and Barbara Seliger. Identification of novel

microRNAs regulating HLA-G expression and their clinical relevance in renal cell carcinoma.

206) Federica Bozzano, Francesco Marras, Maria Libera Ascierto, Claudia Cantoni, Giovanni

Cenderello, Chiara Dentone, Antonio Di biagio, Giancarlo Orofino, Eugenio Mantia, Silvia Boni,

Pasqualina De Leo, Antonino Picciotto, Fulvio Braido, Francesca Antonini, Ena Wang, Francesco

Marincola, Lorenzo Moretta, and Andrea De Maria. "Emergency exit" of bone-marrow-resident

CD34+DNAM-1brightCXCR4+ precursors during chronic infection/inflammation supports innate

and adaptive immune responses. Nature Communications, Accepted 20 Jul, 2015

207) Douglas C. Palmer, Geoffrey C. Guittard, Zulmarie Franco, Shashank J. Patel, Heather D.

Hickman, Yun Ji, Nicolas Van Panhuys, Dorina Frasheri, Lindsay M. Garvin, Christopher A.

Klebanoff, Nicolas Acquavella, Luca Gattinoni, Madhusudhanan Sukumar, Joseph G. Crompton,

Robert L. Eil, David Clever, Rahul Roychoudhuri, Rajat Varma, Ena Wang, Francesco M.

Marincola, Lakshmi Balagopalan, Lawrence E. Samelson and Nicholas P. Restifo. Targeted

degradation of PLCγ1 by Cish attenuates CD8+ T cell immunity. The Journal of Experimental

Medicine (JEM), 2015

208) Geok Choo Sim, Chengwen Liu, Ena Wang, Hui Liu, Caitlin Creasy, Zhimin Dai,Willem

Overwijk, Jason Roszik, Francesco Marincola, Patrick Hwu1, Elizabeth Grimm and Laszlo

Radvanyi. Targeting IL-2Rβγ using an IL-2 variant to circumvent the expansion of ICOS+ T 2

regulatory cells and promote NK cell activation. Sumitted to Cancer Immunology Research, 2015

209) Simon Jasinski-Bergner, Adi Reches, Christine Stoehr, Juergen Bukur, Chiara Massa, Verena

Spath, Roland Wartenberg, Helge Taubert, Sven Wach, Bernd Wullich, Ena Wang, Francesco M.

Marincola, Arndt Hartmann, Ofer Mandelboim and Barbara Seliger. Submitted to Oncotarget, 2015

23

210) Matthew J Olnes, Yuri Kotliarov, Angelique Biancotto, Foo Cheung, Ena Wang, John S Tsang,

and Robert Nussenblatt, and the CHI Consortium. Effects of Systemically Administered

Hydrocortisone on the Human Immunome. Sumitted 2015.

211) Ping Jin, Yuanlong Zhao, Hui Liu, Jinguo Chen, Jiaqiang Ren, Jianjian Jin, Davide Bedognetti, Ena

Wang, Francesco Marincola and David Stroncek. Interferon-g and Tumor Necrosis Factor-a

Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype. Submitted, 2015

212) Rahul Roychoudhuri, Robert L. Eil, David Clever, Gautam Mehta, Christopher A. Klebanoff,

Madhusudhanan Sukumar, Zhiya Yu, Hui Liu, Ping Jin,Yun Ji, Douglas C. Palmer, Jenny H. Pan,

Anna Chichura, Joeseph G Crompton, Shashank Patel, David Stroncek, Ena Wang, Franco

Marincola, Luca Gattinoni and Nicholas P. Restifo. The transcription factor BACH2 is required to

establish immunosuppression within tumors. Submitted to JCI. 2015

213) Abeer Fadda, Fiza Butt, Sara Tomei, Amal Robay, Sara Deola, Ronald Crystal, Marios Kambouris,

Ena Wang, Franco Marincola, Khalid Fakhro, Chiara Cugno. Novel DNA Ligase IV mutation

identified in a child exhibiting congenital abnormalities, developmental delay and

immunodeficiency. In preparation. 2015

214) Cara L Haymaker, Richard C Wu, Krit Ritthipichai, Chantale Bernatchez, Marie-Andrée Forget, Jie

Qing Chen, Hui Liu, Ena Wang, Francesco Marincola, Patrick Hwu & Laszlo G Radvanyi. BTLA

marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival

properties. OncoImmunology, 4:8, 2015. e1014246, DOI:10.1080/2162402X.2015.1014246

215) Joseph G. Crompton, Manikandan Narayanan, Suresh Cuddapah, Rahul Roychoudhuri,Yun Ji,

Wenjing Yang, Shashank J. Patel, Madhusudhanan Sukumar, Douglas C. Palmer, Weiqun Peng,

Ena Wang, Francesco M. Marincola, Christopher A. Klebanoff, Keji, Zhao, John Tsang, Luca

Gattinoni, Nicholas P. Restifo. Histone architecture of stem-cell memory T cells reveals progressive

remodeling of epigenetic landscape after activation of CD8 T cells. Cellular & Molecular

Immunology (2015), 1–13.

216) Matthew J. Olnes, Yuri Kotliarov, Angélique Biancotto, Foo Cheung, Jinguo Chen, Rongye Shi,

Huizhi Zhou, Ena Wang, John S. Tsang, Robert Nussenblatt & The CHI Consortium Effects of

Systemically Administered Hydrocortisone on the Human Immunome. Scientific Reports | 6:23002 |

DOI: 10.1038/srep23002

217) Elise P. Salerno, Davide Bedognetti, Ileana S. Mauldin, Donna H. Deacon, Sofia M. Shea, Joel

Pinczewski, George Coukos, Ena Wang, Thomas F. Gajewski, Francesco M. Marincola, Craig L.

Slingluff, Jr. Human melanoma and ovarian cancer cells expressing mechanical barrier molecules are

associated with lack of immune signatures. Submitted 2016

218) Ileana S. Mauldin, Nolan A. Wages, Anne M. Stowman, Ena Wang, Walter C. Olson, Donna H.

Deacon, Kelly T. Smith, Nadedja Galeassi, Jessica E. Teague, Mark E. Smolkin, Rachael A. Clark,

Gina R. Petroni, Francesco M. Marincola, David W. Mullins, and Craig L. Slingluff, Jr. Vaccination

and topical imiquimod treatment promote immune signatures in melanoma. Submitted 2016

24

219) Ileana S. Mauldin, Nolan A. Wages, Anne M. Stowman, Ena Wang, Mark E. Smolkin, Walter C.

Olson, Donna H. Deacon, Kelly T. Smith, Nadedja V. Galeassi, Kimberly A. Chianese‐Bullock, Lynn

T. Dengel, Francesco M. Marincola, Gina R. Petroni, David W. Mullins, and Craig L. Slingluff, Jr.

Intratumoral interferon-gamma increases chemokine production but fails to increase T-cell infiltration

of human melanoma metastases. Submitted 2016

220) Laura Soldati, Sara Tomei, Ena Wang, Abdelhamid Kerkadi, Tahra ElObeid, Paul Amuna, Lotfi

Chouchane, Annalisa Terranegra. Potential nutrigenomic approaches to reduce the high incidence

of obesity in Qatar. J Nutr Food Sci 6:472. doi:10.4172/2155-9600.1000472 2016.

221) Johannes Lawen, Ena Wang, Muhammad Elnaggar, Georg Fieg.Model for de novo mutation

propagation depending on paternal age at conception and associated neurological and psychiatric

disorders. Submitted 2016.

222) Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1

Phenotype" by Ping JIN, Yuanlong Zhao, Hui Liu, Jinguo Chen, Jiaqiang Ren, Jianjian Jin, Davide

Bedognetti, Shutong Liu, Ena Wang, Francesco Marincola, and David Stroncek. Submitted to NPG. Nature

publication group. 2016

223) Lance D. Miller, Jeff A. Chou, Michael A. Black, Cristin Print, Julia Chifman , Angela Alistar, Thomas Putti,

Xiaobo Zhou, Davide Bedognetti, Wouter Hendrickx, Ashok Pullikuth, Jonathan Rennhack, Eran R. Andrechek, Sandra

Demaria, Ena Wang, Francesco M. Marincola. Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers

of Immune Responsiveness. Published OnlineFirst on April 28, 2016; DOI: 10.1158/2326-6066.CIR-15-0149

1) Publications – Peer-Reviewed Review Articles and meeting reportes

1) Wang E., Lake D, Winfield JB and Marchalonis, JJ. IgG autoantibodies to "switch peptide" determinants of

TCR alpha/beta in human pregnancy. Clinical Immunology & Immunopathology, 1994. 73: 224- 8.

2) Wang E and Marincola FM. A natural history of melanoma: Serial tumour gene expression analysis.

Immunology Today. 21 (12): 619-623, 2000.

3) Wang E, Marincola MF. cDNA arrays and the enigma of melanoma immune responsiveness. The Cancer J

Scientific American. 7 (1): 16-23, 2001.

4) Wang E and Adam S. Discrimination of genetic polymorphism using DNA chips. ASHI Quarterly 25 (2):

45-48, 2001.

5) Wang E, Phan GQ and Marincola FM. T-cell directed cancer vaccines. Exp. Opin. Biol Ther. 1 (2): 277-290,

2001.

6) Phan GQ, Wang E and Marincola FM. Immune escape mechanisms in cancer. Exp. Opin. Biol Ther 1 (3):

511-523, 2001.

25

7) Macino B and Wang E. Tricks and pitfalls in the preparation of tetrameric HLA complexes. ASHI Quarterly

25 (4): 143-145.

8) Mocellin S, Panelli MC, Wang E, Nagorsen D and Marincola FM. The dual role of the IL-10 cytokine

network. Trends in Immunol vol.24 (1):36-43. 2003.

9) Nagorsen D, Wang E, Marincola FM and Even J. Transcriptional analysis of tumor-specific T cell responses in

cancer patients. Crit Rev Immunol. 22 (5&6): 449-462, 2002.

10) Wang E, Marincola FM and Klein HG. HLA and platelet transfusion outcome. ASHI Quarterly, 2:56-59,

2002

11) Panelli MC, Wang E, Klein H and Marincola FM. The enigmatic role of interleukin-2 in cancer therapy.

Genome Biology 3 (7): research 0035.1-0035.17, 2002 (Electronic address)

12) Wang E, Panelli MC, Smith K and Marincola FM. Application of Functional Genomics in Oncology.

Principle and Practice of Oncology Update. Vol 16 No.3, 2002.

13) Mocellin S, Wang E, Panelli MC, Rossi CR and Marincola FM. Use of laser scanning cytometry to study the

tumor microenvironment. Histol Histopathol 18 (2): 609-615, 2003.

14) Mocellin S, Panelli MC, Wang E, Rossi CR and Marincola FM. Tumor microenvironment: what have we

learnt studying the immune response in this puzzling battlefield? Tumori, 88:437-444, 2002.

15) Wang E and Marincola FM. Applications of functional genomics in oncology. A follow up. Principles and

Practice of Oncology – Updates. 17 (9): 1-16, 2003.

16) Marincola FM, Wang E, Herlyn M, Seliger B and Ferrone S. Tumors as elusive targets of T-cell based active

immunotherapy. Trends Immunol. 24 (6): 334-341, 2003.

17) Panelli MC, Wang E, Monsurro V and Marincola FM. The role of quantitative PCR for the immune

monitoring of cancer patients. Expert Opin Biol Ther, 2 (5): 537-544, 2002.

18) Wang E. Panelli MC and Marincola FM. The impact of genomics in the technology industry. Exp Opin Biol

Ther. 1 (5): 749-751, 2001.

19) Wang E and Marincola FM. Monitoring peptide-based vaccines with a new eye. Seminar Book of the Annual

Meeting of the American Association of Blood Banks.

20) Monsurró V, Wang E, Panelli MC, Nagorsen D, Jin P, Smith K, Ngalame Y, Even J, Marincola FM. Active-

specific immunization against cancer: is the problem at the receiving end? Sem Cancer Biol, 13: 473-480,

2003.

21) Mocellin S, Wang E, Panelli M, Pilati P and Marincola FM. DNA array-based gene profiling in tumor

immunology. Clin Cancer Res 2004, 10:4597-4606.

22) Nagorsen D, Wang E, Panelli MC. High-throughput genomics: an emerging tool in biology and

immunology. ASHI Q 27 (3): 96-99, 2003.

23) Wang E,. Panelli MC, Monsurró V and Marincola FM. Gene expression profiling of anti-cancer immune

responses. Current Opinion in Molecular Therapeutics, 2004, 6:288-295.

26

24) Jing P, Panelli MC, Marincola FM and Wang E. Cytokine polymorphism and is possible impact on cancer.

Immunologic Research, 30 (2): 181-190, 2004.

25) Jin P and Wang E. Polymorphism in clinical immunology-From HLA typing to immunogenetic profiling. J

Transl Med. 1:8, 2003.

26) Wang E, Panelli MC, Monsurro V, Jin P, Zavaglia K and Marincola FM. Current Perspectives in Cell Based

Therapy. Yonsei Medical Journal 2004, Vol 45(3).

27) Wang E, Panelli MC, Monsurro V and Marincola FM. A global approach to tumor immunology. Cellular &

Molecular Immunology 2004, 1(4):1-10

28) Panelli MC, Wang E, Monsurró, Jin P, Zavaglia K, Smith K, Ngalame Y and Marincola FM. Vaccination

with T-cell defined antigens. Exp Opin Biol Ther. 4(5): 697-707, 2004.

29) Wang E, Panelli MC, Monsurró V, Jin P, Zavaglia K and Marincola FM. Immune monitoring of cancer

vaccines. Yonsei Medical Journal, 45, suppl:S71-2, 2004

30) Panelli MC, Nagorsen D, Wang E, Monsurró V, Jin P, Zavaglia K, Smith K, Ngalame Y and Marincola FM.

Mechanism of immune response during immunotherapy. Yonsei Medical Journal, 45: Suppl: S15-17, 2004

31) Panelli MC, Wang E, Monsurro V, Jin P, Zavaglia K, Smith K, Ngalame Y and Marincola FM. Overview of

melanoma vaccines and promising approaches. Curr Oncol Rep 6 (5): 414-420, 2004

32) Marincola FM, Wang E and Atkins MC. 18th Annual scientific meeting of the international society for

biological therapy of cancer. Expert Opin. Biol.Ther. 4(1):1-8, 2004.

33) Wang E and Falus A. Changing paradigm through a genome-based approach to clinical and basic

immunology. J Transl Med 2004, 2:2

34) Lotze TM, Wang E, Marincola FM, Hanna N, Panelli PC, Weinstein J, Perricone MA, Shivers SC, Bugelski

PJ, Sauter G, Burns CA, Howell M, Damle N, Taylor L, Godfrey T, Petricoin E, Scheibenbogen C, Whiteside

TL, and Coukos G. Report from the International Society for the Biologic Therapy of Cancer-Workshop on

Cancer Biometrics: Identifying Biomarkers and Surrogates of Tumors in Patients. A meeting held at the Masur

Auditorium, National Institutes of Health 2003. J Immunother 2005, 28 (2):79-119

35) Wang E, Panelli MC and Marincola FM. High throughput views of cancer immune responsiveness. Enhancer

– Biotherapy of Cancer 3(1):19-21, 2005

36) Panelli MC, Wang E and Marincola FM. Eclectic effects of systemic interleukin-2 administration in the

context of melanoma specific immunization. Enhancer – Biotherapy of Cancer 3(1):21-24, 2005

37) Wang E, Panelli MC and Marincola FM. Gene profiling of immune responses against tumors. Current

Opinion in Immunology 2005, 17:423–427

38) Wang E. RNA amplification for successful gene profiling analysis. Journal of Translational Medicine. 3:28,

2005

27

39) Wang E, Panelli MC and Marincola FM. Autologous tumor rejection in humans: trimming the myths –

Immunol Invest – 35(3): 437-458, 2006

40) Jin P, Wang E, Provenzano M, Stroncek D and Marincola FM. Gene expression signatures of initerleukin-2 in

vivo and in vitro and their relation to anticancer therapy. Critical reviews in Immunology, 27(5):437-448, 2007

41) Jin P and Wang E – Expanding the horizons of immune polymorphism – ASHI Q 2Q:48-51, 2006

42) Wang E, Panelli M, Marincola FM. Complementary techniques: RNA amplification for gene profiling

analysis. Avd Exp Med Biol. 2007, 593:39-53

43) Selleri S, Rumio C, Sabatino M, Marincola FM and Wang E. Tumor Microenvironment and the Immune

Response. Surg Oncol Clin N Am 16: 737–753, 2007

44) Wang E, Selleri S, Sabatino M, Monaco A, and Marincola FM. Spontaneous and Treatment-Induced Cancer

Rejection in Humans. Expert Opinion on Biological Therapy, March 2008, Vol. 8, No. 3 , Pages 337-349

(doi:10.1517/14712598.8.3.337)

45) Stroncek DF, Jin P, Wang E and Jett B. Potency Testing of Cellular therapies: The Emerging role of Molecular

Assays. J Transl Med. 2007 May 30;5:24.

46) Wang E, Sabatino M and Marincola FM. Immunonics of immune rejection. Clinical Immunomics. Falus A Ed.

Springer, New York, NY, 87-105, 2008

47) Wang E, Worschech A and Marincola FM – The immunological constant of rejection. Trends in Immunol – 29

(6):256-262, 2008

48) Wang E, Selleri S, Sabatino M, Monaco A, Pos Z and Marincola FM. Spontaneous and treatment-induced

cancer rejection in humans. Exp Opin Biol Ther – 8 (3): 337-349, 2008

49) Selleri S, Rumio C, Sabatino M, Marincola FM and Wang E. Tumor microenvironment and the immune

response. Surg Oncol Clin N Am 16:737-753, 2007

50) Wang E and Marincola FM. Bottom up: a modular review of immunology. Immunity 29:9-11 2008

51) Butterfield LH, Disis ML, Fox ba, Lee PP, Khleif SN, , Thurin M, Trinchieri G, Wang E, Wigginton J,

Chaussabel D, Coukos G, Dhodapkar M, Hakansson L, Janetzki S, Kleen T, Kirkwood J, Maccalli C, Maecker

H, Maio M, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S,

Slingluff Jr.CL, Stroncek DF, Streicher H, Xu X, Zeskind B, Zhao Y, Zwierzina H, Marincola FM. A

systematic approach to biomarker discovery; preamble to “the iSBTc-FDA task force on immunotherapy

biomarkers. J Transl Med– 6: 81, 2008

52) Wang E, Albini A, Stroncek DF and Marincola FM. A new take on comparative immunology; relevance to

immunotherapy – Immunotherapy- 1(3): 355-366, 2009

53) Wang E, Monaco A, Monsurró V, Sabatino M, Pos Z, Uccellini L, Wang J, Worschech A, Stroncek DF &

Marincola FM. Antitumor vaccines, immunotherapy and the immunological constant of rejection. IDrugs 2009

12(5): 297-301

54) Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM,

Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi

28

M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L,

Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H,

Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek

DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB,

Marincola FM. Emerging concepts in biomarker discovery; The US-Japan Workshop on Immunological

Molecular Markers in Oncology. Commentary. JTM 2009, 7:45. doi:10.1186/1479-5876-7

55) Stroncek DF, Jin P, Ren J, Feng J, Castiello L, Civini S, Wang E, Marincola FM, Sabatino M. Quality

assessment of cellular therapies: the emerging role of molecular assays. Korean J Hematol. 2010 Mar;45(1):14-

22.

56) Bedognetti D, Sertoli MR, Wang E and Marincola FM. Gene expression profiling in vaccine therapy and

immunotherapy of cancer. Exp Rev Vaccines – 9 (6): 555-565, 2010

57) Ascierto PA, De Maio E, Bertuzzi S, Palmieri G, Halaban R, Hendrix M, Kashani-sabet M, Ferrone S, Wang

E, Cochran A, Rivoltini L, Lee PP, Fox BA, Kirkwood JM, Ullmann CD, Lehmann FF, Sznol M,

Schwartzentruber DJ, Maio M, Flaherty K, Galon J, Ribas A, Yang J, Stroncek DF, Mozzillo N, Marincola

FM. - Future Perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge

Naples-USA. Naples, December 6th-7 th2010". – J Transl Med 2011 Mar 26;9(1):32

58) Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, Tomei S, Fox BA, Gajewski TF,

Marincola FM, Butterfield LH. SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online

Resources and Useful Tools—A Compass in the Land of Biomarker Discovery. J Transl Med – 9: 155, 2011

59) Wang E and Marincola FM – Applying the uncertainty principle to immunology – Immunotherapy. 2011

Oct;3(10):1127-8

60) Bedognetti D, Wang E, Sertoli MR and Marincola FM. Gene-expression profiling in vaccine therapy and

immunotherapy for cancer. Expert Review of Vaccines, June 2010, Vol. 9, No. 6, Pages 555-565 , DOI

10.1586/erv.10.55 (doi:10.1586/erv.10.55)

61) Wang X, Wang E, Marincola FM. Translational medicine is developing in China: A new venue for

collaboration. J Transl Med 2011 Jan 4th; 9:3

62) Qian M, Wu D, Wang E, Marincola FM, Wang W, Rhodes W, Liebman M, Bai C, Lam CW, Marko-Varga G,

Fehniger TE, Andersson R, Wang X. Development and Promotion in Translational Medicine: Perspectives

from 2012 Sino-American Symposium on Clinical and Translational Medicine 2012, 1:25

63) Wang X, Wang E, Marincola FM - Translational Medicine is developing in China: a new venue for

collaboration – J Transl Med – 9:3, 2011

64) Wang E, Uccellini L, Marincola FM. A genetic inference on cancer immune responsiveness.

Oncoimmunology. 2012 Jul 1;1(4):520-525.

65) Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald

JE, Gogas H, Grossmann K, Huaschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais

R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N and Marincola FM –

Future Perspectives in Melanoma Research – J Transl Med – 10 (1): 83, 2012

66) Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G,

Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV,

29

Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C,

Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S,

Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R,

Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN,

Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto

PA, Fox BA. Cancer classification using the Immunoscore: A worldwide task force. JTM 2012, 10:205

67) Wang E, Tomei S and Marincola FM – Reflections upon human cancer immune responsiveness to T cell-

based therapy – Cancer Immunol Immunother – 61(6): 761-70; 2012

68) Chen X, Andersson R, Cho WCS, Christiani D, Coico R, Drazen J, Ege M, Gao H, Jin K, Liebman MN,

Marraro G, Marko-Varga G, Marincola FM, Popescu LM, Spada C, Shahzad A, Wang E, Wang W, Wang X,

Wang Y-X, Xia J, Qu J. The international effort: building the bridge for translational medicine: report of the 1st

International Conference of Translational Medicine. Clin Transl Med. 2012 Aug 14;1(1):15.

69) Tomei S, Wang E, Delogu LG, Marincola FM and Bedognetti D – Non-BRAF-targeted therapy,

immunotherapy and combination therapy for melanoma –Expert Opin Biol Ther. 2014 May;14(5):663-86. doi:

10.1517/14712598.2014.890586.

70) Overwijk WW, Wang E, Marincola FM, Rammensee HG, Restifo NP. Mining the mutanome: developing

highly personalized Immunotherapies based on mutational analysis of tumors. J Immunother Cancer. 2013 Jul

29;1:11. doi: 10.1186/2051-1426-1-11. eCollection 2013.

71) Wang E, Bedognetti D, Tomei S, Marincola FM. Common pathways to tumor rejection. Ann N Y Acad Sci.

2013 May;1284:75-9. doi: 10.1111/nyas.12063.

72) Howard B. Dickler, J. Phillip McCoy, Robert Nussenblatt, Shira Perl, Pam Schwartzberg, John Tsang, Ena

Wang and Neil Young. The National Institutes of Health Center for Human Immunology, Autoimmunity, and

Inflammation: history and progress. Ann. N.Y. Acad. Sci. ISSN 0077-8923 Issue: The Year in Immunology

73) Ena Wang, Davide Bedognetti, Francesco M. Marincola. Prediction of Response to Anticancer

Immunotherapy Using Gene Signatures. Journal of Clinical Oncology, Vol 31:1-3, 2013

74) Lionel Apetoh, Mark J. Smyth, Charles Drake, Jean-Pierre Abastado, Ron N. Apte, Maha Ayyoub, Jean-Yves

Blay, Marc Bonneville, Lisa H. Butterfield, Anne Caignard, Chiara Castelli, Federica Cavallo, Esteban Celis,

Lieping Chen, Mario Colombo, Begonya Comin-Anduix, Georges Coukos, Madhav V. Dhodapkar, Glenn

Dranoff, Ian Frazer, Wolf-Hervé Fridman, Dmitry I. Gabrilovich, Eli Gilboa, Sacha Gnjatic, Dirk Jäger, Pawel

Kalinski, Howard L. Kaufman, Rolf Kiessling, John Kirkwood, Alexander Knuth, Roland Liblau, Michael T

Lotze, Enrico Lugli, Francesco Marincola, Ignacio Melero, Cornelis J. Melief, Thorsten Mempel, Elisabet A.

Mittendorf, Kunle Odnusi, Willem Overwijk, Anna Karolina Palucka, Giorgio Parmiani, Antoni Ribas, Pedro

Romero, Robert D. Schreiber, Gerold Schuler, Pramod K. Srivastava, Eric Tartour, Danila Valmori, Sjoerd

Van der Burg, Pierre Van der Bruggen, Benoît Van den Eynde, Ena Wang, Weiping Zou, Cassian Yee,

Theresa L. Whiteside, Daniel Speiser, Drew M. Pardoll, Nicholas P. Restifo, and Ana C. Anderson. Consensus

nomenclature for CD8 T cell phenotypes in cancer. Oncoimmunol 04/2015; 4(4):e998535.

75) Bernard A. Fox, Ena Wang and Jianda Yuan. Immune Monitoring Technology Primer. SITC

76) Jianda Yuan, Priti Hegde, Raphael Clynes, Periklis Foukas, Alexandre Harari, Thomas O. Kleen, Pia

Kvistborg, Cristina Maccalli, Holden T. Maecker, David B. Page, Harlan Robins, Wenru Song, Edward C.

Stack, Ena Wang, Theresa L. Whiteside, Yingdong Zhao, Heinz Zwierzina, Lisa H. Butterfield, Bernard A.

30

Fox. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. Submitted to

JITC 2015.

77) Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH,

Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar

MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman

HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ,

Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber

RD, Schuler G, Srivastava PK, Tartour E, Valmori D, vander Burg SH, van der Bruggen P, van den Eynde BJ,

Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC. Consensus nomenclature

for CD8⁺ T cell phenotypes in cancer. Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection

2015 Apr. PMID: 26137416

Book Editors:

1. Francesco M. Marincola and Ena Wang. Immunologic signatures of rejection. Springer Publisher, New York,

Dordrecht Heidelberg, London 2010

2. Ena Wang, Paolo A. Ascierto and David F. Stroncek. New Developments in T Cell Based Anti Cancer

Immunotherapies. Springer Publisher, NY 2016

Book Chapters

1) Wang E and Marincola FM. Amplification of small quantities of mRNA for transcript analysis. In DNA

Arrays – A Molecular Cloning Manual. Protocol 16, pp 204-213, David Bowtell and Joseph Sambrook

Editors, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2002.

2) Wang E and Marincola FM. Monitoring peptide-based vaccines with a new eye. In Cellular Therapy: New

Frontiers In Transfusion Medicine. Published by the American Association of Blood Banks, Bethesda,

Maryland. Chapter 5, pp 77-92, 2002.

3) Wang E and Marincola FM. Molecular portraits of metastatic melanoma in vivo. Gene Targeting and

Functional Genomics. Page 11. Editors: Xiao Y, Deng CX and Yie JS , Beijing China, May 2001.

4) Wang E, Panelli MC, Smith K and Marincola FM. Applications of functional genomics in oncology. Principle

and Practice of Oncology Updates. 16(3): 2002.

5) Wang E, Panelli MC and Marincola FM. Marincola. Genomic Analysis of Cancer. Principle and practice of

Oncology update Vol 7 No 9, 2003.

6) Wang E and Marincola FM. The development and reversal of T-cell tolerance in cancer patients receiving

peptide-based vaccines. In Cancer Immunotherapy at the Crossroads. JH Finke & RM Bukowski Eds. Humana

Press, Totowa, NJ. Chapter 13, pp 237-255, 2004.

7) Wang E and Marincola FM. Human Leukocyte Antigen (HLA) System. In Hematology – Basic principles and

Practice. Churchill Livingstone Press (Elsevier Science). 2004, Fourth Edition.

8) Wang E and Marincola FM. A microarray-based screening method for known and novel SNPs. In DNA

Microarrays – Advanced Methods. Ulrike Nuber Editor, BIOS Scientific Publishers Limited, Taylor & Francis,

Abingdon Chapter 6, pp 69-86, 2005.

31

9) Wang E and Marincola FM. A microarray-based screening method for known and novel SNPs in “DNA

Microarrays”, BIOS Scientific Publisher Limited, Taylor & Francis Group, NY, NY and Abingdon, UK –

Chapter 6, pp 65-81, 2005.

10) Panelli MC, Wang E and Marincola FM – Immune response to cancer: science and myth: Assessing the

dynamics of human tumor and host interactions in real-time. In 2005 ASCO Educational Book, Perry MC

Editor, American Society of Clinical Oncology, Alexandria, VA page 224-228, 2005

11) Wang E. Gene profiling approaches for the monitoring of anti-cancer immune responses. Analyzing T cell

responses-how to analyze cellular immune responses against tumor associated antigens. Edited by Dir Nagorsen

and F.M. Marincola. Springer publisher, Dordrecht, The Netherlands. Chapter 17 Microarrays, pp285-301,

2005.

12) Wang E, Panelli MC and Marincola FM. RNA amplification. Microarray Technology and Cancer Gene

Profiling.. Series: Advances in Experimental Medicine and Biology, Vol. 593 2007, XVIII, 159 p. 37 Simone

Mocellin Editor. Landes Bioscience publisher 2005

13) Wang E, Panelli MC and Marincola FM. Understanding the response to immunotherapy in humans. Springer

Semin Immun. 27:105-117, 2005

14) Wang E, Adams S, Marincola FM and Stroncek DF. Leukocyte Antigens: Human Leukocyte Antigen (HLA)

and Human Neutrophils Antigen (HNA) Systems. In Hillyer C, Silberstein L, Ness P, Anderson K, editors.

Blood Banking and Transfusion Medicine: Basic Principals and Practices, Second Edition. Elsevier Inc.

Philadelphia, PA 2005.

15) Wang E and Marincola FM. Immune Responsiveness of Human Tumors. Immunogenomics and Disease.

Andras Falus Editor, John Wiley & Sons, Ltd. Chapter 7, pp133-151, 2005.

16) Belardelli F, Aricó E, Marincola F and Wang E. Clinical trials using IFN-a as a vaccine adjuvant: new strategies

for the molecular monitoring of the immune responses. In Rapporti ISTISAN; ISS.NIH Collaborative Program

Progress Report. Garaci E, D’Addazio C and Giuliano F Eds, ISTASAN Publisher, Rome 2007. Chapter 5,

pages 26-30, 2007.

17) Ena Wang, Ping Jin, Hui Liu and Francesco M Marincola. cDNA and microarray-based technologies. Edited

by Dr. Gires and Seliger. Tumour-associated antigens.WILEY-VCH Veriag GmbH & Co. KGaA, Weinheim,

Published Online: 27 OCT 2009, DOI: 10.1002/9783527625970.ch5

18) Slezak SL, Wang E, Stroncek DF and Marincola FM. Analysis of vaccine-induced T cells in humans with

cancer – in Memory T cells, Zanetti M Editor, Landes Bioscience, Austin, TX – 2010.

19) Stroncek DF, Jin P, Wang E, Ren J and Marincola FM. Potency analysis of cellular therapies: the role of

molecular assays. In Principles of Translational Science in Medicine: from Bench to Bedside. Martin Wehling,

Editor, Cambridge University Press, Cambridge UK – ISBN:9780521888691, Publication date: June 2010

20) Liu Q, Sabatino M, Stroncek D, Marincola FM and Wang E. Melanoma stem cells and biomarkers – in

“Diagnostic and prognostic biomarkers and therapeutic targets in melanoma”. Michael Murphy Ed. – Springer

Science/Human Press Publisher – 2011.

21) Wang E and Marincola FM – From the “delayed allergy reaction” to the “immunologic constant of rejection”;

foreword. In Immunologic signatures of rejection, Wang E and Marincola FM Eds. – Springer Publisher – 2010

32

22) Wang E and Marincola FM – Immune-mediated tumor rejection. Chapter in Wang E and Marincola FM Eds. –

Springer Publisher New York Dordrecht Heidelberg, London 3-8, 2010

23) Jin P, Liu Q, Sabatino M, Stroncek DF, Marincola FM and Wang E. Melanoma Stem Cells and Niche. Elison

Allan Ed. – Springer Science/Human Press Publisher – 2011.

24) Bedognetti D, Marincola FM, Wang E, Ascierto ML. Molecular Profiling of Immunotherapeutic Resistance. In

“Cancer Immunotherapy: Immune Suppression and Tumor Growth, 2nd Edition. GC Prendergast and EM Jaffee

Eds, Elsevier, under revision”.

25) Bedognetti D, Wang E, Sertoli MR, Marincola FM. Melanoma and biomarkers of immunoresponsiveness. In:

“Emerging therapeutics for melanoma”. FM Marincola, PA Ascierto and J Kirkwood Eds, Future Medicine Ltd,

London UK 2012.

26) Ascierto ML, Marincola FM and Wang E. Immunologic Interpretation of Cancer Biology: Impact on Clinical

Outcome. The Tumor Immunoenvironment. Springer science. 2013

27) Ascierto ML, Marincola FM and Wang E - Immunologic interpretation of cancer biology: impact on clinical

outcome. In “The tumor microenvironment”- MR Shurin Ed, Springer Publisher, Chapter 4, 2013

28) Wang E and Marincola FM. Tumor immune responsiveness – In Immunogenomics and Human Disease – Falus

A Editor – John Wiley & Sibs, Ltd. London UK. In press.

29) Bedognetti D, Wang E, Sertoli MR and Marincola FM – Melanoma and biomarkers of immune responsiveness:

predicting the clinical outcome of immunotherapy – in Advances in Melanoma Treatment, Ascierto P,

Kirkwood J and Marincola FM Eds. – Future Science Group Publisher- London UK – in press (book Chapter)

Presentations as invited speaker:

1) Dissecting the molecular immunology of T cell-based vaccines. Immunology and cell biology seminar. The

Wistar Institute, Philadelphia, November 3rd, 2000.

2) Evolving molecular portrait of metastatic melanoma. U.S.-Japan Cooperative Cancer Research Program

Workshop. February 17th through 18th 2001.

3) Antisense RNA amplification for high-throughput gene profiling analysis. Cold Spring Harbor Laboratory

Workshop on molecular methods for microarray analysis. Cold Spring Harbor, NY. April 20th to 21st 2001.

4) Evolving molecular portraits of metastatic melanoma. FOCIS annual conference. Symposium speaker. Boston.

May 4-7th, 2001.

5) Molecular portraits of metastatic melanoma in vivo. The Sixth Homeland and Oversea Forum on Life Sciences

Symposium on gene targeting and functional genomics. Beijing China, May 22-24th, 2001.

6) Molecular profiling of metastatic melanoma in vivo during immune therapy. International Meeting on

Cancer: from Basic Research to Clinical application. Bari, Italy July 20-21, 2001 (Invited speaker).

33

7) Dissection cancer immune biology at genomic level. Genome Institute of Singapore. Singapore. Feb 28th-

March 5th 2002.

8) Pushing to the limits of Functional genomics. Baylor Research Institute. Dulles, Texas. March 27th-28th, 2002.

9) Analysis of the Microenvironment Relevant to Ovarian Cancer. M.D. Anderson Cancer Center, Texas.

August 26th -27th, 2003.

10) Evaluating the cellular immune response to melanoma in the context of clinical trials. Perspectives in

melanoma VI. Miami, Florida. November 13-14, 2003.

11) Application of functional genomic in melanoma and NPC study. Cancer Research Institute of Hunan Medical

University, Key Lab of Carcinogenesis of Ministry of Public Health, Changsha, Hunan, China. January 25th -

27th, 2004.

12) Novel application of functional genomic in cancer research. Cancer Institute, Cancer Center, SunYat-Sen

University, Guangzhou, China. January 27th-28th, 2004.

13) Apply integromic strategy in cancer research. Cancer institute, the First Military Medical University, Tonghe,

Guangzhou, China. January 29th-31st, 2004.

14) A genomic approach to cancer research. Institute of Basic Medical Sciences, Chinese Academy of Medical

Sciences, School of Basic Medicine, Peking Union Medical Collage. Beijing China. February 2nd -3rd, 2004.

15) The use of the microarrays technology for the molecular tracking of the anti-tumor immune response.

International meeting on cancer vaccines. National Cancer Institute, Roma, Italy. April 19-20th, 2004.

16) Strategy for analyzing heterogeneity of immune response associated with cytokine polymorphism. Italy-USA

workshop on Immunology and Immunotherapy of Cancer. Istituto Superiore di Sanita, April 21, 2004.

17) Novel application of Integromics in cancer research. Department of Oncology and Surgical Sciences, Padova

Medical University. April 22, 2004.

18) Integromics approaches to dissect genetic and functional heterogeneity between immune polymorphism of

Caucasian. The 1st International Conference on Basic and Clinical Immunogenomics. Budapest, Hungary.

October 3rd-7th, 2004.

19) Gene Profiling in Cancer Research-DNA microarrays: Principle and Applications (Bio-Trac 24 course

lecture). Foundation for advance education in the sciences, INC. National Institute of Health, MD 20892.

20) Emerging molecular technologies-Current Topics in Histocompatibility for Technologists audio conference

series. Georgetown University. June 15, 2004.

21) Comprehensive Monitoring of Cancer Vaccines. IMMUNOTHERAPEUTICS. September 20-21, 2004

Fairmont Copley Plaza • Boston, Massachusetts.

22) Integromics approaches to dissect genetic and functional heterogeneities between Caucasian and Asian

immune responses. The 1st International Conference on Basic and Clinical Immunogenomics, 3-7 October,

2004, in Budapest, Hungary.

34

23) Looking for the constant endogenous reference genes for real time PCR. UCSF Immune Tolerance

Network/Tolerance Assay Group. February 22, 2005, Bethesda, MD

24) Extensive monitor immune reponse ex vivo. April 21, 2005. School of Basic medicine, Peking Union Medical

College. Beijing China.

25) A global approach to the multidimensional analysis and its relevance to human immune response. April 25,

2005. Southern Medical University, Guangzhou, China.

26) A global approach to the multidimensional analysis and its relevance to human immune response. April 27,

2005. Cancer Center, Cancer Institute, Sun Yat-sen University, Guangzhou, China.

27) Assessing the dynamics of human tumor and host interactions in real-time. The 41st Annual meeting of

American Society of Clinical Oncology (ASCO). May 16, 2005. Orlando, FL.

28) Exploring immune rejection ex vivo in real time. Symposium “Tumor immunology meets oncology II”, May

19-20th, 2006. Martin Luther University, Halle-Wittenberg University Hospital, Germany.

29) Interactive gene profiling of mouse immune responses against human cancer xenografts induced by GLV-

1h68 inoculums. Genelux Corporation Scientific Advisory Board (SAB) meeting. September 16-18, 2006.

San Diego Science Center.

30) Clonal Persistence and Evolution of Genetic Alterations over a Decade of Recurrent Melanoma. Chietti

Research center. Dec 5th 2006, Chietti, Italy.

31) Genetic Alterations over a decade of recurrent melanoma. Italian Melanoma Intergroup 12th Annual meeting

2006. Nov30th -Dec 3rd 2006, Bari Italy.

32) Molecular profiling of melanoma. CP-675,206 Correlative Science Board meeting. May 14, 2007. Westin

Copley Place, Boston, Massachusetts.

33) miRNA profiling and cancer. Minisymposium. Clinic Applications of MiroRNA analysis. May 29th, 2007.

UPMC Shadyside Herberman Conference Center, Pittsburgh, PA.

34) Clonal Persistence and Evolution of Genetic Alterations over a Decade of Recurrent Melanoma. Genelux

Advisory board meeting. Oct 26-28, 2007. Miramonte Resort & Spa, Palm Springs, California.

35) miRNA Profiling analysis comparing GI 101A vs TH29 post virotherapy. Genelux Advisory board meeting.

Oct 26-28, 2007. Miramonte Resort & Spa, Palm Springs, California.

36) Utilization of amplification tools for the real-time analysis of small clinical samples. Profiling of immune

response to guide cancer diagnosis, prognosis, and prediction of therapy. November 27, 28, 2007. The

Embassy Suites Hotel, Washington, DC.

37) RNA amplification as an essential approach for biomarker discovery. Translational Medicine: Bridging the

Gap between Discovery and Development that is being held March 25-28th, 2008 in San Francisco, CA

38) Multilevel Genetic Alterations over a Decade of Recurrent Melanoma Suggesting Stem Cell Persistence.

Tumor Immunology meets oncology IV. May 22nd -24th 2008. Martin Luther University, Halle-Wittenberg

University Hospital, Germany.

35

39) Micro RNA and their role in tumor progression and ontogeny. Genelux Scientific meeting. May 29-31, 2008.

Genelux, San Diego CA

40) The treatment effects of PYH906, CPT-11 and CPT + 906 combinational therapy on Colon 38 tumor.

Immunogenetics lab and Yale collaboration retreat. September 26, 2008. Bethesda, MD. NIH-CC-DTM.

41) Multilevel Genetic Alterations over a Decade of Recurrent Melanoma Suggest Stem Cell Persistence.

Southern Medical University, Guangzhou, P. R. China 2008

42) A global approach for translational research. Translational Cancer Care: Preventive and therapeutic

opportunities in gene-environment interaction and immunotherapy. Cancer Research Center of Hawaii Feb

17-18 2009

43) Genomic and Transcriptional Evolution of Metastatic Melanoma: A Case Report. Clinical Center Grand

Rounds, Wednesday, June 3, 2009, Lipsett Amphitheater, Clinical Center, Building 10.

44) Genomic and Transcriptional Evolution of Metastatic Melanoma: A Case Report. NHGRI, Friday June 12th

2009, Building 49 conference room.

45) Genomic analysis platforms and application at Center for Human Immunology. 1106 Scientific workshop,

Mannkind Corporation. Valencia, CA. Jan 4th, 2010.

46) Genomic and Transcriptional Evolution of Metastatic Melanoma: A Case Report. Bioinformatics interest

group meeting. Wednesday, March 17th, 2010. NIH library conference room.

47) Systems Biology of the Human Immune Response and the new Trans-NIH Center for Human Immunology

[CHI]. June 14th, 2010. Cancer Research Institute, Southern Medical University, Guangzhou, Guangdong

Province, 510515 P.R.China

48) Systems Biology of the Human Immune Response and the new Trans-NIH Center for Human Immunology

[CHI]. June 10th, 2010. Xiamen University, Fujian Province, P.R.China

49) Systems Biology of the Human Immune Response and the new Trans-NIH Center for Human Immunology

[CHI]. June 3rd, Institute of Basic Medical Science Academy of Medical Science & School of Basic Medicine

Peking Union Medical College. P.R. China.

50) Systems biology using Omics in study TCM. August 23-25, 2010, the 9th CGCM meeting at Hong Kong

Convention Center.

51) Looking for Biomarkers of Immune Responsiveness. Dec 6-7, 2010. Melanoma Research :a bridge Naples-

U.S.A, Naples, Italy

52) Looking for Biomarkers of immune-mediated tumor rejection. Tumor Immunology meets Oncology VI.

April 15th-16th, 2011. Martin Luther University, Halle-Wittenberg University Hospital, Germany.

53) DNA micro array technology. April 29th-May 3rd, 2011 MOLECULAR AND TRANSLATIONAL

ONCOLOGY WORKSHOP. Chaminade Conference Center

54) A global approach for translational research. April 29th-May 3rd, 2011 MOLECULAR AND

TRANSLATIONAL ONCOLOGY WORKSHOP. Chaminade Conference Center.

36

55) Translational Medicine. April 29th-May 3rd, 2011 MOLECULAR AND TRANSLATIONAL ONCOLOGY

WORKSHOP. Chaminade Conference Center.

56) A lean Strategy to study the complexity of human cancer. Lean Oncology - Naples, Italy. 6-8 October 2011

57) A system approach to study human immune response. Shenzhen Institute of XiangYa Biomedicine, China.

Oct. 17-19th. 2011

58) Omics application in translational medicine. International Conference of Translational Medicine, Wenzhou,

China. Oct 22-23, 2011.

59) A Strategy to study the complexity of human cancer. Reijin Hospital, Shanghai China. Oct 24-25, 2011

60) Immunologic heterogeneity of melanoma. MELANOMA RESEARCH: A bridge from Naples to the World.

Naples, December 5th-6th, 2011

61) Immunotherapy efficacy challenged by Immunologic Heterogeneity. The world cancer immunotherapy

conference. Challenges and opportunities in clinical development, clinical trial design and commercialization.

San Diego, CA. Jan 25-26, 2012.

62) Paradigm shift in Translational Medicine powered by computation and bioinformatics. The 2nd international

conference "Open Source for Computer-Aided Translational medicine (OSCAT2012). The Institute of

Microbial Technology (IMTECH), Chandigarh, India. February 22-25, 2012,

63) Profiling the tumor microenvironment. Changing the tumor microenvironment: New strategies for

immunotherapy meeting. Pamplona Spain. 21-22 March 2012

64) DNA micro array technology. MOLECULAR AND TRANSLATIONAL ONCOLOGY WORKSHOP.

Cancer Education Consortium. Sanibel Harbour Marriott, FL. May 19- 22nd, 2012.

65) A global approach for translational research. April 29th-May 3rd, 2011 MOLECULAR AND

TRANSLATIONAL ONCOLOGY WORKSHOP. Cancer Education Consortium. Sanibel Harbour Marriott,

FL. May 19- 22nd, 2012.

66) Translational Medicine. April 29th-May 3rd, 2011 MOLECULAR AND TRANSLATIONAL ONCOLOGY

WORKSHOP. Cancer Education Consortium. Sanibel Harbour Marriott, FL. May 19- 22nd, 2012.

67) Translational medicine from observation to hypothesis to interpretation. The second USA-Sino-CTM

meeting. Shanghai China, June 27-30, 2012

68) The complexity of tumor biology challenges immune responsiveness. The 3rd. MELANOMA RESEARCH: A

bridge from Naples to the World. Naples, December 2 -5th, 2012.

69) A panoramic view of tumor rejection induced by immunotherapy. NCI, Old Medical Board Room, Jan 17th

2013

70) Genetic Inference about Cancer Immune Responsiveness. TRIG-hosted lecture. Building 10 Lipsett

Amphitheater. NIH. June 13, 2013.

37

71) CANCER IMMUNITY AND IMMUNOTHERAPY: Application of high through put sequencing technology

in clinical studies. Int Summer Course on Frontiers in Translational Medicine. Madrid July 17th, 2013

72) Translational Medicine Today. Colloquium on Biological and medical Mass Spectrometry, Center of

Excellence in Biological and Medical Mass Spectrometry at Lund University, Lund Nov 15-16, 2013

73) Research and development update. Sidra Medical Research Center Majlis. April 2014.

74) Global analyses of human immunome reveal heterogenetic immune response and baseline predictors of the

post‐vaccination response. Trends in Biomedical Research and Scholarly Publishing. Four Seasons, Doha,

Qatar. April 24, 2014

75) Genome Qatar: A pilot study for Personalized Medicine and Precision Health. Board Institute. Oct. 7th 2014.

76) The power and need of understand your genome. Mini UYG symposium. Four Seasons, Doha, Qatar. October

29, 2014

77) Open remark at Advances in proteomic and personalized medicine symposium. Doha Qatar. Nov. 16th, 2014,

78) Decipher immune responsiveness by multidimensional Omic analysis. International Forum of Precision

Medicine Clinical Applications. Shanghai Fudan University, Zhong Shan Hospital. May 26th 2015.

79) The Qatar Genome Project: Introducing Genome-Guided Medicine at Population Scale. Big Genomics in

Practice: The Integrated and Efficient Use of Massive NGS Data for Diagnostics and Discovery. Baltimore,

US. Oct 6-10, 2015 ASHG

80) The Qatar Genome Project: Introducing Genome-Guided Medicine at Population Scale. Seminars in

Molecular Mecicine. University of Magna Graecia Catanzaro, Italy. Oct 11th 2015.

81) Genome-Guided Medicine at Population Scale. CEBMMS symposius 17th March, 2016. Center of Excellence

in Biological & Medical Mass Spectrometry. Lund Univeristy, Sweden.

82) The Qatar Genome Project: Introducing Genome-Guided Medicine at Population Scale. Center of Systems

mMedicine, Chinese Academy of Medical Sciences, Sushou Institute of Systems Medicine. China. May 11th,

2016.

Abstracts and Poster presentations

1) Marincola FM, Lee K-H, Panelli M., Riker A, Kammula U and Wang E. NCI Combined Intramural Principal

Investigator Retreat. January 7-8, 1999.

2) Lee K-H, Wang E., Garboczi DN, Steinberg, S.M., Rosenberg SA and Marincola FM. T cell expansion in vivo

after peptide vaccination against melanoma: frequency determination of epitope-specific CTL using tetramer

HLA (tHLA). Annual American Association of Immunologists Meeting, Washington D.C. April 17-21, 1999.

Accepted as late, breaking abstract.

3) Riker AI, Panelli MC, Kammula U, Wang E., LeeK-H, Steinberg SM, Rosenberg Sa and Marincola FM.

Immune selection following antigen specific immunotherapy of melanoma. Accepted for oral presentation at

60th Annual Meeting of the Society of University Surgeons, New Orleans, Feb 10-13, 1999 (abstract in press).

38

4) Bettinotti MP, Panelli M, Lee K-H, Wang E, Stroncek D and Marincola FM. Flu M158-66 immunogenicity in

association with HLA-A*0205 is facilitated by the concomitant presence of HLA-A*0201. ASHI 1999.

5) Jiang Y, Chen Y, Su Y, Wang E, Marincola FM, Dougherty ER, Meltzer PS, Bittner M. and Trent JM.

Evaluating altered levels of gene expression in cancer cells. 1999. Microarray meeting.

6) Bettinotti MP, Wang E, Monsourro’ V, Hadzikadic L and Marincola FM. Lack of correlation between

FLU/HLA-A*0201 or A*0205 tetrameric complexes staining and immunogenicity of Flu-M158-66 in HLA-

A*0201 and A*0205 bearing individuals. Presented at annual AAI meeting, FASEB J. 14 (6): 97-8, A1056,

2000

7) Monsurro’ V, Nielson M-B, Lee K-H, Wang E and Marincola FM. Modulation of vaccine-specific T cell

frequency and TCE repertoire during epitope-based vaccination. Presented at annual AAI meeting, FASEB J.

14(6): 147-19, A1139, 2000

8) Mocellin S., Ohnmacht G, Wang E and Marincola FM. Kinetics of IL-10 and TGF-beta expression in

metastases of patients with melanoma undergoing IL-2 based therapy. Submitted to ACS.

9) Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch PA, Rosenberg SA and Marincola FM. Tumors

that undergo complete response experience preferential decrease in expression of melanoma differentiation

antigens. Submitted to ACS.

10) Wang E, Miller LD, Ohnmancht GA, Fung B, Villa J, Bittner M and Marincola FM. Gene expression profiling

by microarray using amplified mRNA. NCI combined intramural principal investigator retreat: January 6-7,

2000.

11) Mocellin S., Ohnmacht G, Wang E and Marincola FM. Use of Laser Cytometry for analysis of small tumor

samples. Annual meeting of the Society of Surgical Oncology, 2001.

12) Wang E, Miller LD, Ohnmacht GA, Mocellin S, Simon R, Zhao Y, Powell JI, Asaki E, Alexander RH, Duray

P, Liu ET, Rosenberg SA, Marincola FM. Prospective gene profiling of melanoma identifies classifiers of

immune responsiveness. Presented at “Genetic Mechanisms in Cancer” 53rd Annual Symposium on

Fundamental Cancer Research. Houston Texas November 14-17, 2000. Oral presentation, recipient of Travel

Award.

13) Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Simon R, Zhao Y, Powell JI, Asaki E,

Alexander RH, Duray P, Liu ET, Rosenberg SA, Marincola FM. Molecular portraits of metastatic melanoma

in vivo. Presented at US- Japan Cancer Seminar (Maui, February 17-18, 2001). (Invited speaker)

14) Wang E and Marincola FM. Transcript amplification for high-throughput functional genomics. Workshop on

high-throughput technology. Cold Spring Harbor Laboratory. April 2001(Invited speaker).

15) Wang E, Miller L. Liu E and Marincola FM. Evolving molecular portraits of metastatic melanoma. FOCIS

annual conference. Symposium speaker. Recipient of Travel Award.

16) Wang E, and Marincola FM. Molecular profiling of metastatic melanoma in vivo during immune therapy.

International Meeting on Cancer: from Basic Research to Clinical application. Bari, Italy July 20-21, 2001

(Invited speaker).

17) Wang E and Marincola FM. Molecular portraits of metastatic melanoma in vivo. Gene Targeting and

Functional Genomics. Beijing China, , 2001.

39

18) Panelli MC, Wang E, Phan Y, Miller L, Ohnmacht GA, Smith K, Rosenberg SA and Marincola FM. Functional

genomics of systemic IL-2 administration in humans. Submitted to ASHI 2001.

19) Wang E, Panelli M, Smith K and Marincola F. Evolving molecular portraits of metastatic melanoma. The 8th

World Congress on Cancers of the skin. Zurich, July 18-21, 2001.

20) Panelli MC, Wang E, Phan G, Miller L, Ohnmacht GA, Smith K, Rosenberg SA, and Marincola FM.

Functional Genomics of Systemic IL-2 Administration in Humans. ASHI 27th Annual Meeting. Oral

presentation/ Basic Science: New technology in Major Histocompatibility complex studies. October 13-17,

2001.

21) Panelli MC, Wang E, Phan G, Mille L, Ohnmacht GA, Smith K, Rosenberg SA, and Marincola FM.

Functional Genomics of Systemic IL-2 Administration in Humans. Poster Presentation for Fellows Travel

Award for Research Excellence 2002. The fifth James A. Shannon Lecture, National Institutes of Health,

Bethesda, November 27, 2001.

22) Smith K, Panelli MC, Wunderlich JR, Marincola FM and Wang E. Binomial Distribution of Metastatic

Melanoma Profiles In Vitro. Oral and poster presentation. Minority Trainee Research Forum, San Diego,

March 16-18, 2002. As preceptor of the Recipient of minority award.

23) Wang E, Panelli MC, Monsurro V, Smith K, Nagorsen D, Even J and Marincola FM. Tumor Host Interaction

in vivo. Premiere Journees des Cordeliers, Paris, May 8-11, 2002.

24) Panelli MC, Martin B, Nagorsen D, Wang E, Smith K and Marincola FM. Genomic and proteomic profiling

of PBMC and tumor microenvironment following stimulation with high doses IL-2. The 17 annual meeting of

the society for biological therapy, La Jolla CA, Nov 7-10 2002.

25) Ena Wang, Sharon Adams and Francesco M Marincola Fluorimetric detection of single nucleotide

polymorphism (SNP) by proportional hybridization to oligonucleotide arrays (PHOA). Poster presentation.

The ASHI 28th Annual Meeting, Nashville, TN. Oct 19-23,2000

26) Wang E, Panelli MC, Monsurro’ V, Smith K, Nagorsen D, Even J and Marincola FM. Tumor host interactions

in vivo. Presented at the XIV Pezcoller Symposium on: “The novel dichotomy of immune interactions in

tumors”. The Pezcoller Foundation J. 10 (18): 14-15, 2002.

27) Wang E, Panelli MC, Mocellin S and Marincola FM. What can we learn from gene profiling for classification

and therapy of melanoma? Proceeding of the 2nd International Symposium on Molecular Diagnostics and Skin

Gene Therapy. Düsseldorf March 27th – 29th 2003. J Gene Med 5 (3): s9-s10

28) Wang E, Panelli MC, Monsurro V, Jin P and Marincola FM. A dynamic picture of the tumor

microenvironment. First international melanoma research congress. Phladelphia, PA. June 21-24, 2003

29) Nagorsen D, Monsurro’ V, Wang E and Marincola FM. Characterization of CD8 negative, HLA class I/epitope

tetrameric complexes binding T cells. Society for Biological Therapy, San Diego, November 2002. J

Immunother 25 (6): S2.

30) Panelli MC, Martin B, Nagorsen D, Wang E, Smith K and Marincola FM Genomic and proteomic profiling of

PBMC and tumor microenvironment following stimulation with high doses of IL-2. Society for Biological

Therapy, San Diego, November 2002. J Immunother 25 (6): S3.

40

31) Monsurro’ V, Wang E, Jacobson S and Marincola FM. Genetic profiling of antigen-specific circulating CD8+

cells in humans. Selected for oral presentation at the Annual Meeting of the American Association of

Immunologists, Denver Colorado 2003.

32) Monsurro V, Wang E, Panelli MC, Nagorsen D, Ping Jin, Zavaglia K, Smith K, Ngalame Y and Marincola

FM. Active-specific immunization against cancer: is the problem at the receiving end?” Keynote speaker at

the Biotherapy of Cancer: from disease to targeted treatment. Munich, September 10th – 13th 2003

33) Nagorsen D, Wang E, Monsurro V, Marincola FM and Panelli MC. Polarized macrophage response to

cytokine stimulation. Poster presentation at the 18th annual meeting of the Society of Biological Therapy of

Cancer, Bethesda, MD 2003. Journal Immunotherapy 26 (6): s11, 2003

34) Monsurro’ V, Wang E, Yamono Y, Migueles S, Panelli M, Smith K, Nagorsen D, Connors M, Jacobson S and

Marincola FM. Quiescent phenotype of tumor-specific CD8+ T cells following immunization. the 18th annual

meeting of the Society of Biological Therapy of Cancer, Bethesda, MD 2003. Journal Immunotherapy 26 (6):

s11, 2003

35) Wang E, Panelli MC, Monsurró V, Nagorsen D, Ping J and Marincola FM. Polymorphism and Immunology:

Beyond HLA. Immunehematology and blood transfusion. 22nd Annual Symposium. National Institutes of

Health. Bethesda, MD.

36) Wang, E and Weinstein, J. “Genomic analysis of cancer”. Cancer Biometrics Workshop: identifying

biomarkers & surrogates of tumor in patients with cancer. October 30th 2003 – NIH - Bethesda, Maryland.

Page 32-37, Proceedings.

37) Wang E, Panelli MC, Monsurro V, Nagorsen D, Jin P, Smith K, Nagalame Y, Zavaglia K and Marincoal FM.

Evaluating the cellular immune response to melanoma in the context of clinical trials. The perspectives in

Melanoma VI. November 13-14, 2003. Miami, Florida.

38) Wang E, Nglame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary C, Freedman RS

and Marincola FM. Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. The

95th Annual meeting of American Association for Cancer Research. March 27-31, 2004. Orlando, Florida.

Poster presentation.

39) Conejero-Goldberg C, Wang E, Yi C, Goldberg T, Marincola FM, Webster MJ, Yolken RH and Torrey EF.

VIRAL DETECTION ARRAYS: APPLICATION TO SCHIZOPHRENIA. 2003.

40) Ena Wang, Monica C. Panelli, Vladia Monsurro, Ping Jin. Katia Zavaglia and Francesco M. Marincola.

Immune monitoring of cancer vaccines. Yonsei Biomedical Symposium 2004. Centennial Hall, Yonsei

University, Korea, Feb 20-21, 2004.

41) Monica C. Panelli, Dirk Nagorsen, Ena Wang, Vladia Monsurro, Ping Jin, Katia Zavaglia Kina Smith,

Yvonne Ngalame and Francesco M. Marincola. Mechanism of immune response during immunotherapy. Yonsei

Biomedical Symposium 2004. Centennial Hall, Yonsei University, Korea, Feb 20-21, 2004.

42) Ena Wang, Monica C Panelli, Vladia Monsurró, Jin Ping, Katia Zavaglia and Francesco M Marincola.

Tumor microenvironment and immune responses to tumor antigen-specific immunization. International

meeting on cancer vaccines 2004. Istituto Superiore di Sanita, Rome, April 19-20 2004.

41

43) Ena Wang, Monica C Panelli, Vladia Monsurró, Jin Ping, Katia Zavaglia and Francesco M Marincola. The

use of micro array technology for the molecular tracking of anti-tumor immune responses. International

meeting on cancer vaccines 2004. Istituto Superiore di Sanita, Rome, April 19-20 2004.

44) Ena Wang, Monica C Panelli, Vladia Monsurró, Jin Ping, Katia Zavaglia and Francesco M Marincola.

Adjuvant immunotherapy for solid tumors: from promise to clinical application. First Euro-Mediterranean

Congress: new targets in cancer therapy. Sousse Tunisia, May 20-22, 2004.

45) Ena Wang and Francesco M Marincola. Comprehensive Monitoring of Cancer Vaccines.

IMMUNOTHERAPEUTICS. September 20-21, 2004 • Fairmont Copley Plaza • Boston, Massachusetts.

46) Ping Jin, Maurizio Provenzano, Monica C Panelli, Yvonne Ngalame, Francesco M Marincola and Ena

Wang. Integromics approaches to dissect genetic and functional heterogeneities between Caucasian and

Asian immune responses. The 1st International Conference on Basic and Clinical Immunogenomics, 3-7

October, 2004, in Budapest, Hungary.

47) Jin P, Provenzano M, Panelli MC, Ngalame Y, Marincola FM and Wang E. Integromics approaches to

dissect genetic and functional heterogeneities between Caucasian and asian immune responses. Late Breaking

Abstract Oral Presentation, First International Conference on Basic and Clinical Immunogenomics, Budapest,

3-7 October 2004. Tissue Antigens: 64: 322, 2004.

48) Wang E, Panelli MC, Monsurro V, Jin P, Zavaglia K and Marincola FM. The enigma of tumor immune

responsiveness: a high-throughput genomics question? Invited Presentation - First International Conference

on Basic and Clinical Immunogenomics, Budapest, 3-7 October 2004. Tissue Antigens: 64: 340, 2004.

49) Stroncek D, Basil C, Marincola FM, Nagorsen D, Deola S, Smith K, Wang E and Panelli MC. Response of

polarized-macrophages to interferon stimulation. Presented at the 19th annual meeting of the International

Society of Biological Therapy. J Immunother 27 (6): S16, 2004.

50) Voiculescu S, Wang E, Robbins P, Panelli MC, Jin P, Smith K, Nicholoff B and Marincola FM. Clonality

of Melanoma Metastases over a Decade of Recurrent Disease: a Case Report. NIH Postbaccalaureate IRTA

Fellowship poster presentation day, 3 May 2005. As Preceptor.

51) Panelli MC, Wang E and Marincola FM. Assessing the dynamics of human tumor and host interactions in

real-time. The 41st Annual meeting of American Society of Clinical Oncology (ASCO). May 16, 2005.

Orlando, FL. ASCO 2005 Educational book, ISSN1548-8748:224-228.

52) Wang E, Panelli MC, Jin P, Zavaglia K, Deola S, Arico E, Li X, Smith K, Voiculescu S and Marincola FM.

Microarrays for the evaluation of gene expression profiles and gene polymorphism in clinical trials of cancer

immunotherapy. Workshop Microarray technologies in clinical oncology: potential and perspectives. Istituto

Superiore di Sanita, Rpme, June 30, 2005. Istisan Congressi 05/C6 ISSN 0393-5620:17.

53) Panelli MC, Rossi L, Martin BM, White RL, Foster M, Hortin GL, Moharram R, Stroncek D, Wang E, and

Marincola FM. Protein microarrays and perspectives of application clinic trials. Workshop Microarray

technologies in clinical oncology: potential and perspectives. Istituto Superiore di Sanita, Rpme, June 30,

2005. Istisan Congressi 05/C6 ISSN 0393-5620:18.

54) Arico E, Parlato S, Capone I, Pucchio TD, Gabriele L, Rivoltini L, Wang E, Panelli MC and Marincola FM.

Microarrays analysis for monitoring the response to interferon. Workshop Microarray technologies in clinical

oncology: potential and perspectives. Istituto Superiore di Sanita, Rpme, June 30, 2005. Istisan Congressi

05/C6 ISSN 0393-5620:19.

42

55) Panelli MC, Stashower M, Slade H, Smith K, NorwooD C, Abati A, Fetsch P, Filie A, Wang E and

Marincola FM. Gene profiling of BCC treated with the immunomodifier Imiquimod (Aldara TM) reveals key

signatures of tumor rejection. The iSBTc 20th annual meeting, November 10-13, 2005. Hilton Alexandria

Mark Center, Alexandria, VA.

56) Maurizio P, Silvia S, Jin P, Wang E, Sharon A, Panelli M, Leitman SF, Stroncek DF and Marincola FM.

COMPREHENSIVE EPITOPE MAPPING OF THE EPSTEIN-BARR VIRUS LATENT MEMBRANE

PROTEIN-2 IN ETHNICALLY DIVERSE POPULATIONS. The iSBTc 20th annual meeting, November 10-

13, 2005. Hilton Alexandria Mark Center, Alexandria, VA.

57) Jin P, Provenzano M, Panelli MC, Voiculescu S, Zavaglia K, Stroncek D, Marincola FM and Wang E.

Molecular pathways of Interleukin-2. The iSBTc 20th annual meeting, November 10-13, 2005. Hilton

Alexandria Mark Center, Alexandria, VA.

58) Wang E, Jin P, Deola S, Selleri S, Ren Jiaqiang, Voiculescu S, Stroncek D and Marincola FM. Gene

expression impacts of interleukin-2 therapy. 11th International Symposium of Immunology, September 20th-

24th, 2006. Granlibakken Resort and Conference Center, Tahoe City, CA.

59) Wang E and Marincola FM. Looking for the immunological constant of rejection. International conference of

immunogenetics and immunomics. A joint meeting of 2nd Basic and clinical immunogenomics and 3rd

Immunoinformatics ( immunomics) conferences. Keynote speaker. Oct8-12, 2006. Budapest, Hungary.

60) Wang E and Marincola FM. Biomarkers in vaccination clinical trials: Predictive of clinical response.

Frontiers of clinical investigation. Host defense 2006: from bench to bedside. Oct 5-7,2006. Estancia Hotel,

La Jolla, CA.

61) Marianna, Yingdong Zhao, Sonia Voiculescu, Brian J Nickoloff, Laszlo Karai, Alessandro Monaco,

Francesca M Marincola , Ena Wang. Genetic Alterations over a decade of recurrent melanoma. Italian

Melanoma Intergroup 12th Annual meeting 2006. Nov30th -Dec 3rd 2006, Bari Italy.

62) Unlu S, Tang S, Wang E, Marinez I and Lotze M. MicroRNAs are induced by mammalian purified HMGB1

(a danger/damage-associated molecule) in human PBMCs. Minisymposium. Clinical applications of

MicroRNA analysis. UPMC Shadyside Herberman Conference Center, Pittsburgh, PA. May 29, 2007.

63) Lichtenfels R, Wang E, Dressler SP, Zobawa M, Ackermann A, Baumgaernter M, Atkins D, Kersten M,

Hesse A, Puttkammer M, Marincola FM, Lottspeich F and Seliger B. Characterization of candidate

biomarkers in metastatic clear renal cell carcinoma lesions using different approaches. The 8th SIENA

MEETING: From Genome to Proteome: Integration and Proteome Completion. Siena Auditorium

Giurisprudenza e Scienze Pol, Italy. 2008 August 31st- September 4th.

64) Seung-Jae Noh, Samuel Miller, Y. Terry lee, Francesco M. Marincola, David F. Stroncek, Christopher Reed,

Ena Wang and Jeffery L. Miller. Fetal-to adult hemoglobin switching is associated with a dramatic up-

regulation of specific micro RNA species in circulation human erythroid cells. ASH annual meeting 2008

65) A. Worschech, N. Chen, Y.A. Yu, Q. Zhang, M. Sabatino, A. Monaco, Z. Pos, H. Liu, R.M. Buller, E. Wang,

A.A. Szalay, F. Marincola. Predicting the immunologic constant of rejection. International Meeting Needs

and Challenges in Translational Medicine: filling the gap between basic research and clinical applications.

Istituto Superiore di Sanità Rome, Italy, October 1-3, 2008

43

66) P. Nistico, E. Proietti, V. Ferraresi, I. Capone, B Palermo, D. Del Bello, F. Moschella, E. Arico, M. Valentini,

L. Bracci, F. Cognetti, A. Felici, M.E. Tosti, M Roselli, E. Wang, F Marincola, P.G. Natali, F. Belardelli.

Combination of immunotherapy with chemotherapy to redirect the antitumor immune response: from

preclinical studies to patients. Istituto Superiore di Sanità Rome, Italy, October 1-3, 2008

67) A. Monaco, F. Marincoal, E. Wang, M.L. Tornesello, R. C. Gallo, G.K. Lewis, F.M. Buonaguro, L.

Buonaguro. Morphogenomic immune responsiveness to preventive/therapeutic vaccines. Istituto Superiore di

Sanità Rome, Italy, October 1-3, 2008

68) V. De Geiorgi, A. Monaco, M.L. Tornesello, F. Isso, L. Buonaguro, E. Wang, F. Marincola, F.M.

Buonaguro. Evaluation of molecular genetic markers involved in the progression from HCV-associated pre-

neoplastic lesions toward hepatocellular carcinoma by cDNA microarray analysis. Istituto Superiore di Sanità

Rome, Italy, October 1-3, 2008

69) Wang E, Worschech A and Marincola FM. Vaccine, Immunotherapy and the Immunologic Constant of

Rejection. Cancer Immunotherapy & Immunomonitoring (CITIM), First International Conference, Kiev,

Ukraine, May 18th – 21st 2009 (Keynote address).

70) Maccalli C, Wang E, Tomaso T, Mazzoleni S, Sovena G, Ferrone S, Galli R , Marincola F, Parmiani G.

Definition of the immunological properties of cancer stem cells isolated from human glioblastoma. iSBTc

24th Annual Meeting October 29-31, 2009 - Washington, D.C.

71) Zoltan Pos, Silvia Selleri, Tara L Spivey, Hui Liu, Andrea Worschech, Marianna Sabatino, Alessandro

Monaco, Andras Falus , Ena Wang, Harvey J Alter, Francesco M Marincola. Race affects clinical

responsiveness to interferon alpha in a disease-dependent fashion. iSBTc 24th Annual Meeting October 29-

31, 2009 - Washington, D.C.

72) Ena Wang, Scott Bussom, Jinguo Chen, Courtney Quinn, Lam Wing, Zaoli Jiang, Dan Xi, Libin Jia, Jeffrey

White, Francesco M. Marincola, and Yung-Chi Cheng. Transcriptional alteration induced by treatment of

traditional Chinese medicine (PHY-906) in colon cancer. iSBTc 24th Annual Meeting October 29-31, 2009 -

Washington, D.C.

73) Worschech A, Ascierto ML, Chen N, Yu YA, Zhang Q, DiPasquale G, Pos Z, Wang E, Szalay AA and

Marincola FM. Cross talk between constitutive anti-viral state in cancer cell lines and the host’s immune

response during oncolytic therapy. iSBTc 24th Annual Meeting October 29-31, 2009 - Washington, D.C

74) Rafael Carretero, Teresa Cabrera, Ana Isabel Rodriguez, Ena Wang, Federico Garrido, Francesco Maria

Marincola. mRNA profile in progressing and regressing metastases after immunotherapy: role of HLA and

immune system in tumor rejection. EFI

75) Madhu S. Gowda, MD , Kamar Godder, Maciej Kmieciak, Andrea Worschech, Ena Wang , Francesco

Marincola, Masoud Manjili. The active components of the immune response differ in low risk vs. high risk

neuroblastoma. Submitted

76) Common signature of rejection. Ena Wang and Francesco M. Marincola. 1st International conference on

transplantomics and biomarkers in organ transplantation. February 24-26, 2010. Parc 55 totel, San Francisco.

77) H. Gogas, E. Wang, A. Monaco, L. Uccellini, C. S. Floudas, Y. Metaxas, U. Dafni, G. Fountzilas, M.

Spyropoulou-Vlachou, F. Marincola, Evaluation of FOXP3 microsatellite polymorphisms in high-risk

melanoma patients receiving adjuvant interferon. June 4 – 8, 2010. McCormick Place Convention Center in Chicago, Illinois.

44

78) E Wang and Francesco M. Marincola. Signature of tumor rejection by immune cells. 5th Meeting on

Combined Biotherapy of Cancer of the Alleanza Contro IL Cancro Program 2. Milano, April 9-10, 2010

79) Pos Z, Thomas J, Selleri S, Spivey T, Wang J, Liu H, Worschech A, Sabatino A, Monaco A, Alter H, Falus

A, Wang E and Marincola FM – Impact of race on interferon- -wide study –

FOCIS 2010 Annual Meeting – Clin Immunol 135 (s): T23: S45, 2010

80) Ascierto M, Worschech A, Pos Z, Rossano F, Ascierto P, Wang E, Marincola FM – Variations in vaccinia

-

microglobulin - Clin Immunol 135 (s): T96: S65, 2010

81) Ena Wang, Scott Bussom, Jinguo Chen, Courtney Quinn, Lam Wing, Fulan Guan, Zaoli Jiang, Jeffry White,

Francesco M Marincola and Yung-Chi Cheng - Immunologic complexity of tumor, spleen and liver

transcriptional program in mice treated with chemotherapy and traditional Chinese Medicine (PHY-906). The

9th CGCM meeting, Hong Kong, August 23-25, 2010.

82) Bedognetti D, Uccellini L, Wang E, Dudley M, Pos Z, Ascierto ML, De Giorgi V, Liu H, Chen J, Sertoli

MR, Marincola FM and Rosenberg SA. Evaluation of CXCR3 and CCR5 Polymorphisms and Gene-

expression as Predictive Biomarkers of Clinical Response to Adoptive Therapy in Melanoma Patients J

Immunother 33 (8): 860, 2010 – Travel Award Winner, 2010 Annual Meeting of the International Society for

the Biological Therapy of Cancer.

83) Thomas JM, Pos Z, Wang RY, Wang E, Lusso P, Alter HJ, Marincola FM - High-Throughput Analysis of

Plasmacytoid Dendritic Cells Reveals Differential Responses to Discrete Viral Entities - J Immunother 33

(8): 880, 2010 – 2010 Annual Meeting of the International Society for the Biological Therapy of Cancer

84) Ascierto ML, Kmieciak M, Idowu M, Grimes M, Dumur M, Wang E, Marincola FM, Bear HD, Manjili MH -

Signatures of Immune Function Genes Associated with Recurrence-Free Survival in Breast Cancer Patients -

J Immunother 33 (8): 881, 2010 – Travel Award Winner, 2010 Annual Meeting of the International Society

for the Biological Therapy of Cancer.

85) De Giorgi V, Ascierto ML, Pos Z, Buonaguro L, Buonaguro FM, Wang E, Marincola FM - Melanoma and

IRFs: A New Classification of Melanoma – J Immunother 33 (8): 885, 2010 – 2010 Annual Meeting of the

International Society for the Biological Therapy of Cancer

86) Ascierto ML, Worschech A, Castiello L, Wang R, Pos Z, Uccellini L, Bedognetti D, De Giorgi V, Thomas J,

Yuz, Z, Balachandran S, Rossano F, Restifo N, Szalay A, Ascierto P, Wang E, Marincol FM - IKK Complex

and NF-kB: Linkage Between Innate Immune Response and Oncolytic Based Viral Therapy - J Immunother

33 (8): 891, 2010 – 2010 Annual Meeting of the International Society for the Biological Therapy of Cancer

87) Maccalli C, Di Tomaso T, Wang E, Mazzoleni S, Sovena G, Galli R, Marincola FM, Parmiani G -

Immunomodulation of T Cell-Mediated Activity by Cancer Stem Cells Isolated from Human Glioblastoma - J

Immunother 33 (8): 902, 2010 – 2010 Annual Meeting of the International Society for the Biological Therapy

of Cancer

88) Wang E, Gogas H, Monaco A, Uccellini U, Floudas CS Metaxas Y, Dafni U, Fountzilas G, Spyropoulou-

Vlachou M, Marincola FM - Evaluation of FOXP3 Microsatellite Polymorphisms in High-Risk elanoma

Patients Receiving Adjuvant Interferon - J Immunother 33 (8): 912, 2010 – 2010 Annual Meeting of the

International Society for the Biological Therapy of Cancer

45

89) Melissa Rotunno, Yingdong Zhao, Andrew W. Bergen, Jill Koshiol, Laurie Burdette, Maurizia Rubagotti, R.

Ilona Linnoila, Francesco M. Marincola, Pier Alberto Bertazzi, Angela C. Pesatori, Neil E. Caporaso, Lisa M.

McShane, Ena Wang, Maria Teresa Landi - Inherited polymorphisms in the RNA-mediated interference

machinery affect microRNA expression and lung cancer survival. The American Society of Human genetics

(ASHG) 60th annual meeting. Washington DC, Nov 2-6, 2010.

90) Longo, Diane; Ptacek, Jason; Cordeiro, James; Pos, Zoltan; Wang, Ena; Marincola, Francesco; Cesano,

Alessandra. Mapping immune cell signaling network responses using single cell network profiling (SCNP) in

peripheral blood mononuclear cells from healthy donors: defining “normal”. The Clinical Immunology

Society (CIS) 2nd Annual Meeting, Chicago, IL May 19 - 22, 2011.

91) Matthew J. Olnes, Angelique Biancotto, Ena Wang , Robert Reger, Shira Perl, Howard Dickler, J. Phillip

McCoy, Richard Childs, and Neal S. Young. Systemically Administered Hydrocortisone Exerts Differential

Effects on Lymphocytes and Natural Killer Cells in Healthy Donors. ASH 49th Annual Meeting, San Diego

CA. December 10-13, 2011

92) Davide Bedognetti, Sara Tomei, Tara L Spivey, Valeria De Giorgi, Maria Libera Ascierto, Ena Wang, Mark

E. Dudley, Lorenzo Uccellini, Mario Roberto Sertoli, Francesco Marincola, Steven A. Rosenberg. Evaluation

of chemokine-ligand pathways in pre-treatment tumor biopsies as predictive biomarker of response to

adoptive therapy in metastatic melanoma patients. AACR annual meeting, Chicago IL. March31-April 4,

2012

93) Maria Libera Ascierto, Michael O Idowu, Yingdong Zhao, Davide Bedognetti, Paolo Antonio Ascierto, Harry

Douglas Bear, Ena Wang, Franco Marincola, Andrea De Maria, Masoud Manjili. NK cell molecular

signatures are involved in favorable prognosis of breast cancer patients. AACR annual meeting, Chicago IL.

March31-April 4, 2012

94) Ena Wang & Francesco M Marincola. A system biology approach for biomarker identification in cancer

immunotherapy. The 2nd international conference "Open Source for Computer-Aided Translational medicine

(OSCAT2012). The Institute of Microbial Technology (IMTECH), Chandigarh, India. February 22-25, 2012.

95) Ena Wang and Francesco M Marincola. A holistic view of tumor rejection. New strategies for

immunotherapy meeting. Pamplona Spain. 21-22 March 2012

96) CHI as team. The blessing of diversity: a systems biology approach to dissect human immune responses using

population variations. FOCIS annual meeting, June 20-23rd, 2012. Vancouver, BC, Canada.

97) Ena Wang and Francesco M. Marincola. The Ying and Yang of tumor microenvironments. 24th EORTC-

NCI-AACR Symposium on ‘Molecular Targets and Cancer Therapeutics’, 6-9 November 2012 in Dublin,

Ireland

98) Ena Wang. The complexity of tumor biology challenges immune responsiveness. The 3rd. MELANOMA

RESEARCH: A bridge from Naples to the World. Naples, December 2nd -5th, 2012.

99) Ena Wang. A panoramic view of tumor rejection induced by immunotherapy. Medical Board Room, Clinical

Cancer Research Branch, National Cancer Institute, NIH. January 17th, 2013

100) P Saenz-Loped, J Reinboth, Al Rodrigues, D Bedognetti, R Carretero, F Marincola, F Garrido, E Wang, T

Cabrera. Comparative gene expression analysis of genes associated with T cells subset in bladder tumors

treated with BCG: association with cancer recurrence. Net working in Immunogenetics. 27th annual EFI

46

European Immunogenetics and Histocompatibility Conference. Maastricht, 11-14 May 2013. Best Post

Award.

101) Valeria De Giorgi PhD, Michele Sommariva PhD, Davide Bedognetti, MD, PhD, Jinguo Chen, Rongye Shi,

Huizhi Zhou, Hui Liu, John Wunderlich, Ena Wang, MD and Francesco Marincola MD. Genomics

characterization of immune status activation in melanoma cell lines. FOCIS, June 25-28, 2014, Chicago,

Illinois. USA

102) Sara Tomei, Ravinder Mamtani, Rashid Al Ali, Maryam Abdulmalik, Awatef Ismail, Sohaila Cheema,

Hekmat A. Rouh, Idil I Aigha, Sura Al-Samraye, Mona Tahar, Nada El Emadi, Azza Al Mujalli, Ahmed

Abdelkerim, Siddik Youssif, Andrea Worschech, Emad El Sebakhy, Ramzi Temanni, Vineesh Khanna, Ena

Wang, Dhanya Kizhakayil, Al-Anood Al-Thani, Mohammed Al-Thani, Albert B. Lowenfels, Francesco M.

Marincola, Javaid Sheikh6 and Lotfi Chouchane. Genome-Wide Association Studies (GWAS) Obesity

Susceptibility Loci in Qataris, a highly Consanguineous Arabian Population. FOCIS, Chicago, Illinois, USA.

June 25-28, 2014.

103) Muna Al Hashmi, Sara Tomei, Valeria De Giorgi, Ena Wang and Francesco M. Marincola. BRAF mutation

analysis: comparison of NGS technology, Sanger sequencing and quantitative Real Time PCR (q-PCR). QF

ARC 2014, Doha Qatar, 2014.

104) Sandra Leisz, Kristin Schulz, Susanne Erb, Peter Oefner, Katja Dettmer, Dimitrios Mougiakakos, Ena

Wang, Francesco M. Marincola, Franziska Stehle and Barbara Seliger. Von Hippel-Lindau gene and

hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects

on cell metabolism. Keyston Symposia. Cancer Immunotherapy: Immunity and Immunosuppression Meet

Targeted Therapies (J6); January 24 - 28, 2016 | Vancouver, British Columbia, Canada.

105) Abeer Fadda, Fiza Butt, Sara Tomei, Amal Robay, Sara Deola, Ronald Crystal, Ena Wang, Khalid Fakhro

and Chiara Cugno. Whole Genome Next Generation Sequencing Identifies Multiple Pathogenic Mutations in

a Patient With Recurrent Infections and Multiple Congenital Anomalies. ASHG 2015, Oct. 6-9, Baltimore,

MD. USA

106) Marios Kambouris, Anna Rajab, Abeer Fadda, Hibah Shaath, Sara Tomei, Yasser Al-Sarraj, Ena Wang,

Hatem El-Shanti. An Insertion Frame-Shift Mutation in PPP1R21 Causes a Novel Autosomal Recessive

Neuro-Developmental Disorder. ASHG 2015, Oct. 6-9, Baltimore, MD. USA

107) Jingxuan Shan, Ramzi Temanni, Wei Liu, Sara Tomei, Puthen V Jithesh, Ravinder Mamtani, Maryam

Abdulmalik, Awatef Ismail, Sohaila Cheema, Hekmat A. Rouh, Sura Al-Samraye, Mona Taher Aseel, Nada

El Emadi, Azza Al Mujalli, Ahmed Abdelkerim, Siddik Youssif, Wanis Ibrahim, Al-Anood Al-Thani,

Mohammed Al-Thani, Albert Lowenfels, Ena Wang, Francesco M. Marincola, Javaid Sheikh, Rashid Al Ali,

and Lotfi Chouchane. Obesity-Susceptibility variants in the Qatari Population: the Whole Genome

Sequencing Approach. HVP annual meeting.

Clinical and Collaborative Studies Participated:

Affiliation PI or protocol number Project name

Intramural collaborations

CCR, NCI Samir N Khleif Anti tumor therapy

Cancer inflammation Noriho Iida EL4 tumors with/without oxaliplatin

47

program, NCI, NIH Rosalba Salcedo Myd88 KO and cancer inflammation

Ludmila Glucan and R484 stimulation in colon cancer

Surgery Branch, NCI,

NIH

James Yang High does IL2 in Melanoma

Steve A. Rosenberg TIL therapy

Madhusudhanan Sukumar Rapamycin mechanism study

Luca Gattinoti T cell biology and differentiation

Doug palmer cis KO on T cell differentiation and activation

Kaiser CD8 T cell polarization

Sid Kerkard IL12 stimulation on T cell

IFNg stimulation on PBMC

Christopher Klebanoff ATRA treatment on CD11+ CD8- and CD11-CD8+ cells

Scott Christopher T cell differentiation status association with effector function

Ruhul Roychoudhuri Zeb2 KO control CD8 T cell differentiation

Bach2 function and it's polymorphism impact on T cell function

Uda Kammula antigen stimulation on Tcm

DCEG, NCI, NIH Tere Landi miR and lung cancer

Tom O'Brien HCV Genotyping for 1720 drug abuser in San Francisco area

Liver Diseases Branch,

NIDDK, NIH Barbara Rehermann

HCV infection in T cells

HBsAg vaccination

NIDDK, NIH Kristin Tarbell STIAG treatment in Type II diebetis

CCR, NCI, NIH Thomas A. Waldmann PHASE I STUDY: IL-15 clinical trial on metastatic cancer

DIR, NIDCR, NIH Tao Cai DKO in Type I diabetics

Center for Human

Immunology (CHI),

NIH

09-H-0239 H1N1 and Seasonal Flu vaccination study

09-H-0245 H1N1 induced Innate immunity study

10-H-0165 Effects of Rosuvastatin on the immune system in healthy volunteers

with normal cholesterol

11-H-0268 The safety and tolerability of ultra low dose interleukin-2

(aldesleukin) in healthy volunteers

11-H-0092 Effects of systemically administered hydrocortisone on the human

immunome in healthy volunteers

10-H-0162

Dysregulation of the Immune System in Hereditary Pulmonary

Fibrosis, Uveitis, Cushing, Multiple sclerosis, system lupus

Trialnet Type I diabetes

Boehm NHLBI Un-diagnosed disease

Tisdale NHLBI Sickle cell transplant

Wiesner NHLBI BTK inhibitor study

10-I-0205 Collection of blood, bone marrow, and buccal mucosa samples

from healthy volunteers for Center for Human Immunology,

Autoimmunity, and Inflammatory Diseases (CHI) protocols

laboratory research studies.

Extramural collaborations

Medical Center, UCLA Antoni Ribas

Therapeutic impact of histone deacetylase inhibitor LAQ824 on

B16 melanoma

Anti-CTLA4 clinic trail

Tumor Vaccine Group,

WASH U

Meredith Slota Imiqumod and Abraxane treatment of inflammatory breast cancer

Medical Center,

UVA

Craig Slingluff

High dose IL-2 clinical study

TLR agonist and antagonist in cancer biology

MD Anderson Cancer

Center

Laszlo Radyanyi BTLA expression association with TIL clinic response

TIL adoptive transfer therapy

Cancer Center, U of

Honolulu

Hai Ning Yan anti-HMGB1 treatment in Mesothelioma

48

Penn Ovarian Cancer

Center

George Coukos Ovarian cancer survival prediction

UPCI Immunologic

Monitoring, UPMC

Lisa H. Butterfield Multiple Antigen-Engineered DC Immunization and IFNa Boost

for Metastatic Melanoma

Surgical oncology,

UPMC

Michael T. Lotze Inflammatory cells in tertiary lymphoid sites and their association

with clinic outcome in pancreas cancer.

Biochemistry

department, Yale U

Yung Chi Cheng PHY96 and chemotherapy on colon cancer

Cancer Institute, NYU

Sandra Demaria Tumor specific antigen stimulation

Sylvia Adams Immunomodulation of breast cancer via TLR7 agonist imiquimod

and radiotherapy’

International collaborations

San Raffaele

Foundation Scientific

Institute, Italy

Cristina Maccalli Cancer stem cells in Glioblastoma

Cancer Center, SMU,

China

Xin Li NPC miR profiling

First Department of

Medicine, U of Athens

Helen Gogas A multi-factorial genetic model for prognostic assessment of

melanoma

Institute of Medical

Immunology, Martin

Luther University

Barbara Seliger

DC maturation for therapeutic application

Genetic alteration association with immune escape

Renal cell carcinoma profiling

APN properties on cellular functions

Characterization of tyrosine kinase (TKI)-regulated proteins

Collaboration with Companies

Aduro BioTech, Inc. Dirk Borckstedt Phase 1B Mesothelioma study

Netherlands Cancer

Institute

Ton Schumacher Melanoma Tumor Samples from NKI

Cel-Sci Eyal Talor Multikine phase III clinical trial on Head and neck cancer